<PAGE> 1
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
November 24, 1998
---------------------------------
(Date of earliest event reported)
ATRIX LABORATORIES, INC.
------------------------------------------------------
(Exact name of Registrant as specified in its charter)
<TABLE>
<CAPTION>
Delaware 0-18231 84-1043826
- ---------------------------- --------------------- ---------------------------------
<S> <C> <C>
(State or Other Jurisdiction (Commission File No.) (IRS Employer Identification No.)
of Incorporation)
</TABLE>
2579 Midpoint Drive, Fort Collins, Colorado 80525
------------------------------------------------------------
(Address of principal executive offices, including zip code)
(970) 482-5868
----------------------------------------------------
(Registrant's telephone number, including area code)
1
<PAGE> 2
ITEM 2. ACQUISITION OR DISPOSITION OF ASSETS.
On November 24, 1998 Atrix Laboratories, Inc. a Delaware corporation
(the "Registrant"), completed the acquisition of ViroTex Corporation, a Delaware
corporation ("ViroTex"), through the merger of its wholly-owned subsidiary,
Atrix Acquisition Corporation, a Delaware corporation, with and into ViroTex.
ViroTex develops over-the-counter and prescription products based on proprietary
drug delivery systems that provide topical and transmucosal delivery of
medications requiring quick onset of action.
Under the terms of the Agreement and Plan of Reorganization dated
November 24, 1998 (the "Merger Agreement"), the stockholders of ViroTex are
entitled to receive $7.5 million in cash and $500,000 in value of shares of the
Registrant's common stock, $.001 par value (the "Common Stock"). In addition,
the ViroTex stockholders are entitled to receive additional consideration of up
to $3,000,000, payable in shares of Common Stock or cash, upon satisfaction of
certain earn-out events set forth in the Merger Agreement related to the
performance of certain products of ViroTex. The Registrant also issued a warrant
to purchase shares of Common Stock in replacement of a warrant to purchase
shares of ViroTex common stock, and agreed to replace certain options held by
employees of Virotex who will become employees or consultants of the Registrant.
Only stockholders of ViroTex who beneficially owned more than 1% of the total
outstanding shares of ViroTex, on a fully diluted basis, as of November 24,
1998, are entitled to receive Common Stock. All other stockholders will receive
cash in lieu of Common Stock. The consideration paid under the Merger Agreement
was determined through arms-length negotiations between the parties and the cash
portion of the purchase price was funded through the Registrant's cash on hand.
The foregoing summary of the Merger Agreement does not purport to be
complete and is subject to, and qualified in its entirety by reference to, the
provisions of the Merger Agreement which is filed as an Exhibit to this Current
Report on Form 8-K .
2
<PAGE> 3
ITEM 7. FINANCIAL STATEMENT, PRO FORMA FINANCIAL INFORMATION AND EXHIBITS
(a) The financial statements of ViroTex will be filed by an
amendment no later than 60 days from the date this Current
Report on Form 8-K must be filed.
(b) The pro forma financial statements of the Registrant will be
filed by an amendment no later than 60 days from the date this
Current Report on Form 8-K must be filed.
(c) Exhibits.
10.1 Agreement and Plan of Reorganization dated November
24, 1998 by and among Atrix Laboratories, Inc., Atrix
Acquisition Corporation and ViroTex Corporation.
10.2 Certificate of Merger of Atrix Acquisition
Corporation and ViroTex Corporation dated November
24, 1998.
99.1 Text of Press Release dated November 30, 1998
3
<PAGE> 4
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized, on this 8th day of December, 1998.
ATRIX LABORATORIES, INC.
By: /s/ BRIAN G. RICHMOND
--------------------------------------
Brian G. Richmond
Vice President, Finance
and Assistant Secretary
4
<PAGE> 5
Exhibit Index
-------------
10.1 Agreement and Plan of Reorganization dated November
24, 1998 by and among Atrix Laboratories, Inc., Atrix
Acquisition Corporation and ViroTex Corporation.
10.2 Certificate of Merger of Atrix Acquisition
Corporation and ViroTex Corporation dated November
24, 1998.
99.1 Text of Press Release dated November 30, 1998
5
<PAGE> 1
EXHIBIT 10.1
AGREEMENT AND PLAN OF REORGANIZATION
BY AND AMONG
ATRIX LABORATORIES, INC.
ATRIX ACQUISITION CORPORATION
AND
VIROTEX CORPORATION
Dated as of November 24, 1998
<PAGE> 2
TABLE OF CONTENTS
<TABLE>
<CAPTION>
Page No.
<S> <C>
ARTICLE I DEFINITIONS.............................................................................................2
ARTICLE II THE MERGER.............................................................................................8
Section 2.01. The Merger.......................................................................................8
Section 2.02. Effective Time...................................................................................8
Section 2.03. Effect of the Merger.............................................................................8
Section 2.04. Effect of Merger on the Capital Stock of the Constituent Corporations............................9
Section 2.05. Merger Consideration............................................................................11
Section 2.06. Payment of Merger Consideration.................................................................16
Section 2.07. Escrow Deposit..................................................................................17
Section 2.08. Dissenting Shares...............................................................................17
Section 2.09. No Further Ownership Rights in Company Capital Stock............................................18
Section 2.10. Lost, Stolen or Destroyed Certificates..........................................................18
Section 2.11. Fractional Shares...............................................................................18
Section 2.12. No Liability....................................................................................18
Section 2.13. Closing Deliveries..............................................................................19
Section 2.14. Taking of Necessary Action; Further Action......................................................20
ARTICLE III REPRESENTATIONS AND WARRANTIES OF THE COMPANY........................................................20
Section 3.01. Organization of the Company.....................................................................20
Section 3.02. Subsidiaries....................................................................................21
Section 3.03. Company Capital Structure.......................................................................21
Section 3.04. Authority.......................................................................................22
Section 3.05. No Conflict.....................................................................................23
Section 3.06. Consents........................................................................................23
Section 3.07. Company Financial Statements....................................................................23
Section 3.08. No Undisclosed Liabilities......................................................................24
Section 3.09. Products/Product Liability......................................................................24
Section 3.10. Loans, Notes, Cash, Accounts Receivable and Accounts Payable....................................25
Section 3.11. Projections.....................................................................................25
Section 3.12. Absence of Certain Changes......................................................................26
Section 3.13. Tax Matters.....................................................................................27
Section 3.14. Restrictions on Business Activities.............................................................30
</TABLE>
<PAGE> 3
<TABLE>
<CAPTION>
Page No.
<S> <C>
Section 3.15. Title of Properties; Absence of Liens and Encumbrances; Condition of Equipment..................30
Section 3.16. Intellectual Property...........................................................................31
Section 3.17. Agreements, Contracts and Commitments...........................................................35
Section 3.18. Interested Party Transactions...................................................................37
Section 3.19. Governmental Authorization......................................................................37
Section 3.20. Regulatory Reports..............................................................................37
Section 3.21. Litigation......................................................................................38
Section 3.22. Minute Books....................................................................................38
Section 3.23. Environmental Matters...........................................................................38
Section 3.24. Brokers' and Finders' Fees and Third Party Expenses.............................................38
Section 3.25. Employee Benefit Plans and Compensation.........................................................39
Section 3.26. Insurance.......................................................................................42
Section 3.27. Compliance with Laws............................................................................43
Section 3.28. Warranties; Indemnities.........................................................................43
Section 3.29. Conflicts of Interest...........................................................................43
Section 3.30. Complete Copies of Materials....................................................................43
Section 3.31. Representations Complete........................................................................43
ARTICLE IV REPRESENTATIONS AND WARRANTIES OF PARENT AND MERGER SUB...............................................44
Section 4.01. Organization, Standing and Power................................................................44
Section 4.02. Authority.......................................................................................44
Section 4.03. Brokers' and Finders Fees.......................................................................44
Section 4.04. No Conflict.....................................................................................44
Section 4.05. Consents........................................................................................45
Section 4.06. Compliance with Laws............................................................................45
Section 4.07. SEC Reports.....................................................................................45
Section 4.08. Financial Capability............................................................................46
Section 4.09. Parent Capital Structure........................................................................46
ARTICLE V ADDITIONAL AGREEMENTS..................................................................................47
Section 5.01. Expenses........................................................................................47
Section 5.02. Public Disclosure...............................................................................47
Section 5.03. S-8 Registration................................................................................47
Section 5.04. Registration Statement..........................................................................47
Section 5.05. Registration Procedures.........................................................................48
Section 5.06. Indemnification.................................................................................50
Section 5.07. Exculpation for Director Liability..............................................................50
Section 5.08. Lease Termination...............................................................................50
Section 5.09. Products Liability Insurance....................................................................51
ARTICLE VI SURVIVAL, INDEMNIFICATION.............................................................................51
</TABLE>
2
<PAGE> 4
<TABLE>
<CAPTION>
Page No.
<S> <C>
ARTICLE VII GENERAL PROVISIONS...................................................................................52
Section 7.01. Notices.........................................................................................52
Section 7.02. Disclosure Schedule.............................................................................53
Section 7.03. Interpretation..................................................................................53
Section 7.04. Counterparts....................................................................................54
Section 7.05. Entire Agreement; Assignment....................................................................54
Section 7.06. Third Party Beneficiaries.......................................................................54
Section 7.07. Severability....................................................................................54
Section 7.08. Other Remedies..................................................................................54
Section 7.09. Governing Law...................................................................................55
Section 7.10. Arbitration.....................................................................................55
Section 7.11. Amendment.......................................................................................55
Section 7.12. Extension: Waiver...............................................................................56
Section 7.13. Rules of Construction...........................................................................56
Section 7.14. Knowledge.......................................................................................56
Exhibit A Form of Personal Services Agreement..................................................A-1
Exhibit B Form of Investment Letter............................................................B-1
Exhibit C Forms of Transmittal Letters.........................................................C-1
Exhibit D Form of Certificate of Merger........................................................D-1
Exhibit E Form of Contingent Escrow Agreement..................................................E-1
Exhibit F Form of Indemnity and Escrow Agreement...............................................F-1
Exhibit G Financial Projections................................................................G-1
Exhibit H Form of Cooley Godward LLP Opinion...................................................H-1
Exhibit I Key Employees........................................................................I-1
Exhibit J Form of Non-Competition Agreement....................................................J-1
Exhibit K Person Executing Personal Services Agreement.........................................K-1
Exhibit L Form of Company Officer's Certificate................................................L-1
Exhibit M [Reserved]...........................................................................M-1
Exhibit N Form of Parent Officer's Certificate.................................................N-1
Exhibit O Form of Morrison & Foerster LLP Opinion..............................................O-1
Exhibit P Form of Assignment and Transfer Agreement............................................P-1
Exhibit Q Form of Consent to Conversion of Preferred Stock.....................................Q-1
Exhibit R Form of Substitute Option Agreement..................................................R-1
Exhibit S Form of Parent Warrant...............................................................S-1
Exhibit T Form of Option Exercise..............................................................T-1
</TABLE>
3
<PAGE> 5
AGREEMENT AND PLAN OF REORGANIZATION
This Agreement and Plan of Reorganization (the "Agreement") is made and
entered into as of November 24, 1998 among Atrix Laboratories, Inc., a Delaware
corporation ("Parent"), Atrix Acquisition Corporation, a Delaware corporation
and a wholly-owned subsidiary of Parent ("Merger Sub"), and ViroTex Corporation,
a Delaware corporation (the "Company").
RECITALS
A. The Boards of Directors of each of the Company, Parent and Merger
Sub believe it is in the best interests of each company and its respective
shareholders that Parent acquire the Company through the statutory merger of
Merger Sub with and into the Company (the "Merger") and, in furtherance thereof,
have approved the Merger.
B. Pursuant to the Merger, among other things, all of the issued and
outstanding common stock of the Company shall be converted into the right to
receive cash and/or shares of the $.001 par value common stock of Parent
("Parent Common Stock"). All outstanding preferred stock, warrants, Cash-Out
Options (defined below) and other securities or instruments convertible into
capital stock of the Company that are not converted into common stock of the
Company or exercised, as applicable, on or prior to the Closing Date shall be
assumed by Parent as set forth herein.
C. A portion of the cash consideration otherwise payable by Parent to
the Principal Stockholders (defined below) in connection with the Merger shall
be placed in escrow by Parent for purposes of satisfying damages, losses,
expenses and other similar charges which result from breaches of
representations, warranties and covenants.
D. The Company and the Principal Stockholders, on the one hand, and
Parent and Merger Sub, on the other hand, desire to make certain
representations, warranties, covenants and other agreements in connection with
the Merger.
NOW, THEREFORE, in consideration of the foregoing recitals and the
covenants, promises and representations set forth herein, and for other good and
valuable consideration, the parties agree as follows:
<PAGE> 6
ARTICLE I
DEFINITIONS
(a) The following terms, as used herein, have the following meanings:
"Acne Product" means the product using the Company's
solvent/microparticulate drug delivery technology containing dapsone
for the topical treatment of human skin disease with an initial
indication for acne.
"Affiliate" means, with respect to any Person, any other Person
directly or indirectly controlling, controlled by, or under common
control with such Person or an officer, director, holder of 10% or
more of the outstanding equity securities of such Person, or an
Immediate Family Member of any of the foregoing.
"Assumed Options" shall mean all unexercised Company Options held
by Jeffrey M. Soinski, Anthony A. Brown, David W. Osborne, Ph.D.,
Meidong Yang, Ph.D. and Gilles Tapolsky, Ph.D. immediately prior to
the Effective Time.
"Balance Sheet Date" means September 30, 1998.
"BEMA" means the Company's proprietary bioerodible mucoadhesive
film.
"BEMA-Dyclonine Canker Sore Disc" means a product using BEMA
technology containing dyclonine cut into discs for the treatment of
canker sores under the OTC monograph for oral care topical analgesics.
"BEMA-Dyclonine Strips" means a proposed Rx product using BEMA
technology containing dyclonine cut into strips for local dental
anesthesia, and requiring submission of a New Drug Application under
current FDA regulations.
"BEMA-Nicotine" means a proposed Rx product using BEMA technology
containing nicotine for smoking cessation, and requiring submission of
a New Drug Application under current FDA regulations.
"Benzocaine Canker Sore Product" means a product using the
Company's proprietary mucocutaneous absorption gel drug delivery
technology containing benzocaine for the topical treatment of canker
sores.
"Cash-Out Options" shall mean all Company Options that are not
Assumed Options.
"CERCLA" means the Comprehensive Environmental Response,
Compensation and Liability Act of 1980, as amended, and any
regulations promulgated thereunder.
2
<PAGE> 7
"Closing Date" means the date of the Closing.
"Code" means the Internal Revenue Code of 1986, as amended.
"Commercialized" means the date on which the Company, its
Affiliates or its sublicensee first sells the relevant Company Product
for use or consumption to an unaffiliated third party in an arms'
length transaction.
"Company Capital Stock" shall mean (i) shares of Company Common
Stock, (ii) shares of Preferred Stock, and (iii) any other capital
stock of the Company.
"Company Common Stock" shall mean shares of common stock of the
Company, $.001 par value per share.
"Company Options" shall mean all issued and outstanding options,
warrants (other than the GulfStar Warrant) or other rights to purchase
Company Capital Stock (whether or not vested) held by consultants,
employees or directors of the Company or any other person.
"Confidential Information" means any information relating to the
properties, prospects, products, services or operations of the Company
or any direct or indirect Affiliate thereof that is not generally
known, is proprietary to the Company or such Affiliate and is made
known to such Person or learned or acquired by such Person while such
Person was an officer, director, employee or independent contractor of
the Company, including, without limitation, information relating to
the software developed by the Company, information as to sources of,
and arrangements for, hardware supplied to customers or clients of the
Company, submission and proposal procedures of the Company, customer
or contact lists, information concerning trade secrets of the Company,
or any of its Affiliates, any improvements relating to the products of
the Company in accounting, marketing, selling, leasing, financing and
other business methods and techniques, and any information obtained by
the Stockholders' Representatives under Section 2.05(e), whether such
information relates to the Company or Parent.
However, Confidential Information shall not include (i) at the
time of disclosure to any Person such information that was in the
public domain or later entered the public domain other than as a
result of a breach of an obligation herein; or (ii) subsequent to
disclosure to any Person, such Person received such information from a
third party under no obligation to maintain such information in
confidence, and the third party came into possession of such
information other than as a result of a breach of an obligation
herein.
"Current Balance Sheet" means the balance sheet of the Company as
of September 30, 1998.
3
<PAGE> 8
"Environmental Laws" means any and all federal, state, local and
foreign statutes, laws, judicial decisions, regulations, ordinances,
rules, judgments, orders, decrees, codes, plans, injunctions, permits,
concessions, grants, franchises, licenses, agreements and governmental
restrictions, now in effect, relating to human health, the environment
or to emissions, discharges or releases of pollutants, contaminants,
Hazardous Substances or wastes into the environment, including without
limitation ambient air, surface water, ground water or land, or
otherwise relating to the manufacture, processing, distribution, use,
treatment, storage, disposal, transport or handling of pollutants,
contaminants, Hazardous Substances or wastes or the clean-up or other
remediation thereof.
"Environmental Liabilities" means any and all liabilities of or
relating to the Company (including any entity which is, in whole or in
part, a predecessor of the Company), whether vested or unvested,
contingent or fixed, actual or potential, known or unknown, which (a)
arise under or relate to matters covered by Environmental Laws and (b)
relate to actions occurring or conditions existing on or prior to the
Closing Date.
"Environmental Permits" means all permits, licenses,
authorizations, certificates and approvals of governmental authorities
relating to or required by Environmental Laws and necessary or proper
for the business of the Company as currently conducted.
"ERISA" means the Employee Retirement Income Security Act of
1974, as amended, together with all regulations promulgated
thereunder.
"Estimated Third Party Expenses" shall equal the amount of Third
Party Expenses of the Company estimated in good faith and based on
reasonable assumptions as of the Closing Date.
"Exchange Act" means the Securities Exchange Act of 1934, as
amended, and the rules and regulations promulgated thereunder.
"External Analgesic Product" means a product using the Company's
proprietary mucocutaneous absorption gel drug delivery technology
using the currently monographed OTC external analgesics as set forth
in 21 CFR section 348 for the topical treatment of arthritis pain,
bursitis, tendonitis, backaches, muscle stains and sprains and muscle
cramps.
"GAAP" means United States generally accepted accounting
principles, consistently applied on a basis consistent throughout the
periods indicated and consistent with each other.
"GulfStar Warrant" means that certain warrant to purchase up to
52,936 shares of Company Common Stock held by the GulfStar Group.
"Hazardous Substances" means any toxic, radioactive, corrosive or
otherwise hazardous substance, including petroleum, its derivatives,
by-products and other hydrocarbons, or any substance having any
constituent elements displaying any of the foregoing characteristics,
including, without limitation, any substance regulated under
Environmental Laws.
4
<PAGE> 9
"Immediate Family Member" means, with respect to any Person, such
Person's spouse, parents, children and siblings.
"Investment Letter" means the investment letter in the form
attached hereto as Exhibit B.
"Lien" means, with respect to any property or asset, any
mortgage, lien, pledge, charge, security interest, encumbrance or
other adverse claim of any kind in respect of such property or asset.
For the purposes of this Agreement, a Person shall be deemed to own
subject to a Lien any property or asset which it has acquired or holds
subject to the interest of a vendor or lessor under any conditional
sale agreement, capital lease or other title retention agreement
relating to such property or asset.
"Material Adverse Effect" means, with respect to any Person, any
material adverse change in, or material adverse effect on, the
business, assets, results of operations, value or financial or other
condition of the Person, or any event or circumstance that would
likely prevent, hinder or materially delay the consummation of any of
the transactions contemplated by this Agreement and the Related
Agreements.
"Minority Stockholder(s)" means those Stockholders of the Company
that individually own 1% or less of the Total Outstanding Shares.
"Parent Common Stock" shall mean unregistered shares of the
common stock, $.001 par value, of Parent.
"Parent Option" shall mean any option to purchase shares of
Parent Common Stock issued pursuant to Section 2.04(c) in connection
with the substitution of an Assumed Option, without any material
changes to the Assumed Option within the meaning of Section 422 of the
Code.
"Parent Warrant" shall mean a warrant to purchase shares of
Parent Common Stock issued pursuant to Section 2.04(f) in connection
with the substitution of the GulfStar Warrant in substantially the
form attached hereto as Exhibit S.
"Person" means an individual, corporation, partnership,
association, trust or other entity or organization, including a
government or political subdivision or an agency or instrumentality
thereof.
"Personal Services Agreement" means the employment agreement in
the form attached hereto as Exhibit A.
5
<PAGE> 10
"Preferred Stock" shall mean shares of Series A, Series B, Series
C, Series D, Series E and Series F Convertible Preferred Stock of the
Company, each with a par value of $.001 per share.
"Principal Stockholder(s)" means those Stockholders of the
Company that individually own more than 1% of the Total Outstanding
Shares.
"Pro Rata Portion" shall mean with respect to each Stockholder an
amount determined at the Effective Time equal to the quotient obtained
by dividing (x) the number of shares of Company Common Stock owned by
such Stockholder immediately prior to the Effective Time, by (y) the
Total Outstanding Shares immediately prior to the Effective Time.
"Related Agreements" shall mean all ancillary agreements required
in this Agreement to be executed and delivered in connection with the
transactions contemplated hereby, including the Escrow Agreement, the
Non-Competition Agreements and the Employment Agreements.
"SEC" means the United States Securities and Exchange Commission.
"Securities Act" means the Securities Act of 1933, as amended,
and the rules and regulations promulgated thereunder.
"Stockholder(s)" means the record owner of shares of Company
Capital Stock.
"Stockholders' Representatives" shall mean William T. Mullaney
and Anthony A. Brown appointed pursuant to the terms and provisions
contained in the Transmittal Letter.
"Subsidiary" means any entity of which securities or other
ownership interests having ordinary voting power to elect a majority
of the board of directors or other persons performing similar
functions are at the time directly or indirectly owned by the Company.
"Topical Antibiotic Product" means a product using the Company's
proprietary topical antibiotic gel technology for currently
monographed OTC topical antibiotic drug ingredients as set forth in 21
CFR section 333.110 and section 333.120 for the topical treatment of
minor cuts, scrapes and burns.
"Total Outstanding Shares" shall be the aggregate number of
shares of Company Common Stock (including any Company Capital Stock
and Company Options) outstanding immediately prior to the Effective
Time.
"Transmittal Letter" means the transmittal letter in the form
attached hereto as Exhibit C.
6
<PAGE> 11
"Wart Removal Product" means a product using the Company's
proprietary topical wart removal technology for currently monographed
OTC topical wart removal ingredients.
"Wound Wash Product" means a product using the Company's
proprietary topical antiseptic technology for currently monographed
OTC topical antiseptic drug ingredients as set forth in 21 CFR section
333.10 and section 333.20 for the topical treatment of minor cuts,
scrapes and burns.
(b) Each of the following terms is defined in the Section set forth
opposite such term below:
<TABLE>
<S> <C>
Aggregate Initial Payment..................................................................Section 2.05(a)
Cash Payment Amount........................................................................Section 2.05(a)
Certificate of Merger.........................................................................Section 2.02
Closing.......................................................................................Section 2.02
Closing Date..................................................................................Section 2.02
Closing Exchange Ratio..................................................................Section 2.05(c)(i)
Company Intellectual Property..........................................................Section 3.16(a)(ii)
Company Payment Amount........................................................................Section 5.01
Company Stock Certificates....................................................................Section 2.05
Conflict......................................................................................Section 3.05
Consent of Conversion of Preferred Stock...................................................Section 3.03(b)
Contingent Escrow Agent................................................................Section 2.06(b)(ii)
Contingent Escrow Agreement............................................................Section 2.06(b)(ii)
Contingent Exchange Ratio.............................................................Section 2.05(c)(iii)
Contract...................................................................................Section 3.17(b)
Customer Information.......................................................................Section 3.15(d)
Delaware Law..................................................................................Section 2.01
Development Obligations....................................................................Section 2.05(e)
Dissenting Shares.............................................................................Section 2.08
Earn-Out Event.............................................................................Section 2.05(b)
Effective Time................................................................................Section 2.02
Escrow........................................................................................Section 2.07
Escrow Agent..................................................................................Section 2.07
Escrow Amount.................................................................................Section 2.07
Escrow Shares..........................................................................Section 2.06(b)(ii)
Exchange Agent................................................................................Section 2.05
Exchange Ratio.........................................................................Section 2.05(c)(ii)
Governmental Entity...........................................................................Section 3.06
Indemnity and Escrow Agreement................................................................Section 2.07
Intellectual Property...................................................................Section 3.16(a)(i)
Interim Financials............................................................................Section 3.07
Merger Consideration..........................................................................Section 2.05
Option Exchange Ratio......................................................................Section 2.04(b)
</TABLE>
7
<PAGE> 12
<TABLE>
<S> <C>
Option Exercise Notice.....................................................................Section 3.03(b)
Option Price...............................................................................Section 2.04(e)
Permitted Assignee....................................................................Section 2.06(b)(iii)
Plan.......................................................................................Section 3.03(b)
Registered Intellectual Property......................................................Section 3.16(a)(iii)
Registered Shares..........................................................................Section 5.04(a)
Registration Statement.....................................................................Section 5.04(a)
Returns................................................................................Section 3.13(a)(ii)
Surviving Corporation.........................................................................Section 2.01
Taxes...................................................................................Section 3.13(a)(i)
Third Party Expenses..........................................................................Section 5.01
Year-End Financials...........................................................................Section 3.07
</TABLE>
ARTICLE II
THE MERGER
Section 2.01. THE MERGER.
At the Effective Time and subject to and upon the terms and conditions
of this Agreement and the applicable provisions of the Delaware Business
Corporation Act ("Delaware Law"), Merger Sub shall be merged with and into the
Company, the separate corporate existence of Merger Sub shall cease and the
Company shall continue as the surviving corporation and as a wholly-owned
subsidiary of Parent. The surviving corporation after the Merger is hereinafter
sometimes referred to as the "Surviving Corporation."
Section 2.02. EFFECTIVE TIME.
The closing of the Merger (the "Closing") will take place concurrently
with the execution of this Agreement at the offices of Morrison & Foerster, LLP,
5200 Republic Place, 370 17th Street, Denver, Colorado, unless another place or
time is agreed to in writing by Parent and the Company. The date upon which the
Closing actually occurs is herein referred to as the "Closing Date" and shall be
no later than December 1, 1998. In addition to the deliveries required by the
parties hereto under Section 2.13 of this Agreement, on the Closing Date, the
parties hereto shall cause the Merger to be consummated by filing a Certificate
of Merger (or like instrument) in the form attached hereto as Exhibit D with the
Secretary of State of the State of Delaware (the "Certificate of Merger"), in
accordance with the applicable provisions of Delaware Law (the time of
acceptance by the Secretary of State of the State of Delaware of such filing
being referred to herein as the "Effective Time").
Section 2.03. EFFECT OF THE MERGER.
(a) General. At the Effective Time, the effect of the Merger
shall be as provided in the applicable provisions of Delaware Law. The
Surviving Corporation may, at any time after the Effective Time, take
any action (including executing and delivering any document) in the
name and on behalf of either the Company or Merger Sub in order to
carry out and effectuate the transactions contemplated by this
Agreement.
8
<PAGE> 13
(b) Certificate of Incorporation. The Certificate of
Incorporation of the Surviving Corporation shall be amended and
restated at and as of the Effective Time to read as did the
Certificate of Incorporation of Merger Sub immediately prior to the
Effective Time (except that the name of the Surviving Corporation
shall remain unchanged).
(c) Bylaws. The Bylaws of the Surviving Corporation shall be
amended and restated at and as of the Effective Time to read as did
the Bylaws of Merger Sub immediately prior to the Effective Time
(except that the name of the Surviving Corporation shall remain
unchanged).
(d) Officers and Directors. The directors and officers of Merger
Sub shall become the directors and officers of the Surviving
Corporation at and as of the Effective Time (retaining their
respective positions and terms of office).
Section 2.04. EFFECT OF MERGER ON THE CAPITAL STOCK OF THE CONSTITUENT
CORPORATIONS.
(a) Effect on Capital Stock. At the Effective Time, by virtue of
the Merger and without any action on the part of the parties hereto,
each share of the Company Common Stock issued and outstanding
immediately prior to the Effective Time (other than any Dissenting
Shares) will be canceled and extinguished and be converted
automatically into the right to receive, without interest, such Merger
Consideration as is payable under Section 2.05, upon the terms and
subject to conditions set forth below and throughout this Agreement.
(b) Assumption of Assumed Options. Upon the Closing, each Assumed
Option will be, in connection with the Merger, replaced by Parent with
a Parent Option. Each Parent Option shall continue to have, and be
subject to, the same terms and conditions as the Assumed Option which
it replaces, except that (i) vesting shall accelerate immediately
prior to the Closing so that the Assumed Options and the Parent
Options which replace them are one hundred percent (100%) vested, (ii)
the per share exercise price under each Parent Option shall be equal
to the number obtained by dividing (A) the exercise price for a share
of Company Common Stock subject to the Assumed Option, by (B) the
Company Common Stock Value (as defined below), (C) multiplied by the
Parent Common Stock Value (as defined below) (rounded up to the
nearest whole cent), and (iii) the Parent Option will be exercisable
for that number of whole shares of Parent Common Stock equal to the
number obtained by multiplying (A) the number of shares of Company
Common Stock subject to the Assumed Option, by (B) the Company Common
Stock Value, divided by (C) the Parent Common Stock Value (rounded
down to the nearest whole share). The "Company Common Stock Value"
shall be determined by dividing (A)(1) the Aggregate Initial Payment,
less (2) Estimated Third Party Expenses in excess of the Company
Payment Amount, plus (3) $1,342,975 by (B) the Total Outstanding
Shares. The "Parent Common Stock Value" shall be equal to the average
closing sale price of a share of Parent Common Stock as reported on
9
<PAGE> 14
the Nasdaq National Market for the twenty (20) consecutive trading
days ending three (3) business days prior to the Closing Date.
Notwithstanding the foregoing, the parties intend that to the extent
that the Assumed Options are incentive stock options, as that term is
defined under Section 422 of the Code, at the time of Closing, that
the Parent Options replacing such Assumed Options also will be
incentive stock options to the same extent.
(c) Assumption Agreement. Promptly following the Closing, Parent
will issue to each holder of an Assumed Option a substitute option
agreement in the form of Exhibit R and each former holder of an
Assumed Option shall acknowledge the receipt of same in exchange for
such holder's Assumed Option.
(d) Option Status. It is the intention of the parties that Parent
Options issued by Parent following the Closing will, to the extent
permitted by applicable law, continue to qualify as incentive stock
options as defined in Section 422 of the Code to the extent the
Assumed Options qualified as incentive stock options immediately prior
to the Closing.
(e) Termination of Cash-Out Options. Parent shall assume and
amend the Cash-Out Options as follows: each Cash-Out Option will
continue to have, and be subject to, the same terms and conditions
including vesting, as provided in the respective option agreements
immediately prior to the Effective Time, except that (A) the Cash-Out
Options will expire on December 8, 1998, unless exercised and (B), at
the option of the holder, the Cash-Out Options will be exercisable for
(1) cash in an amount equal to $1.12 per share of Company Common Stock
underlying the Cash-Out Option immediately prior to the Effective Time
less, the exercise price per share as set forth in the respective
option agreement immediately prior to the Effective Time, or (2) each
option will be exercisable for that number of whole shares of Parent
Common Stock equal to the product obtained by multiplying the Cash-Out
Option Exchange Ratio by the number of shares of Company Common Stock
subject to such Cash-Out Option (rounded to the nearest whole number
of shares of Parent Common Stock), and the per share exercise price
shall be equal to the quotient obtained by dividing the exercise price
for the Cash-Out Option by the Cash-Out Option Exchange Ratio (rounded
to the nearest whole cent). The Cash-Out Option Exchange Ratio shall
mean a number equal to the quotient obtained by dividing (x) the
Aggregate Initial Payment by (y) the average closing sale price of
Atrix Common Stock as reported on the Nasdaq National Market for
twenty (20) consecutive trading days ending three (3) business days
prior to the Closing Date, and dividing such quotient by (z) the Total
Outstanding Shares. In addition, each holder of a Cash-Out Option who
exercises the option shall be entitled to participate in such holder's
pro rata share of the Earn-Out Event payments, if any, under Section
2.05(b) hereof, as if such holder were a Minority Stockholder or
Principal Stockholder, as appropriate, as of the Effective Time, and
shall be treated as a part of the definitions of Principal Stockholder
and Minority Stockholder for purposes of Section 2.06(b) and 2.06(c),
respectively.
(f) Assumption of GulfStar Warrant. Upon the Closing, the
GulfStar Warrant will be, in connection with the Merger, replaced by
Parent with a Parent Warrant in the form of Exhibit S.
10
<PAGE> 15
(g) Capital Stock of Merger Sub. Each share of common stock of
Merger Sub, $.001 par value per share, issued and outstanding
immediately prior to the Effective Time shall be converted into and
exchanged for one validly issued, fully paid and nonassessable share
of common stock of the Surviving Corporation. Each stock certificate
of Merger Sub evidencing ownership of any such shares shall continue
to evidence ownership of such shares of capital stock of the Surviving
Corporation.
Section 2.05. MERGER CONSIDERATION.
As set forth in the Contingent Escrow Agreement, immediately after the
Effective Time, Parent shall deposit with Bank One, Colorado, N.A. (the
"Exchange Agent") (i) the Cash Payment less the Escrow Amount, (ii) certificates
representing $500,000 in value of Parent Common Stock to be issued to the
Principal Stockholders, less cash payments for fractional shares, and (iii) cash
sufficient to make payments in lieu of fractional shares in accordance with
Section 2.11. All of the cash and shares of Parent Common Stock so deposited
with the Exchange Agent, together with any dividends or distributions received
by the Exchange Agent with respect to the shares so deposited, are referred to
collectively as the Exchange Fund. As soon as practicable after the Effective
Time, the Exchange Agent will mail to the registered holders of Company Stock
Certificates (i) a Transmittal Letter, (ii) and instructions for use in
effecting the surrender of Company Stock Certificates in exchange for any cash
payments and, if applicable, certificates representing shares of Parent Common
Stock all in accordance with this Section 2.05. Upon surrender of a Company
Stock Certificate to the Exchange Agent, together with a duly executed Letter of
Transmittal, and such other documents as may reasonably be required by the
Exchange Agent or Parent, (A) the holder of such Company Stock Certificate shall
be entitled to receive in exchange therefor cash and, if applicable, a
certificate representing the number of shares of Parent Common Stock, that such
holder has the right to receive pursuant to this Section 2.05, and (B) the
Company Stock Certificate so surrendered shall be marked "canceled." Until so
surrendered, each outstanding Company Stock Certificate will be deemed for all
corporate purposes, to evidence only the right to receive payment pursuant to
this Article II. In exchange for the Company Stock Certificates, the
Stockholders, excluding holders of Dissenting Shares, shall be entitled to
receive the following consideration (collectively, the "Merger Consideration"):
(a) Initial Payment. $8,000,000, of which $7,500,000, less
Estimated Third Party Expenses in excess of the Company Payment
Amount, shall be payable in cash (the "Cash Payment Amount") and
$500,000 shall be payable in Parent Common Stock (collectively, the
"Aggregate Initial Payment").
(b) Contingent Consideration. In addition, the Stockholders
(which shall include for purposes of this subsection 2.05(b), holders
of Assumed Options, excluding holders of Dissenting Shares, shall be
entitled to receive the following consideration upon satisfaction of
the conditions set forth below (each a "Earn-Out Event"):
(i) $1,000,000 payable in shares of Parent Common Stock or
cash, in the case of the Minority Stockholders, if the Company
11
<PAGE> 16
has entered into a valid and binding definitive agreement to
license or sell its Acne Product prior to December 31, 1999,
which agreement shall contain customary provisions relating to
milestone payments, payment of research and development expenses,
and licensing and royalty fees. Thereafter, this amount shall
decrease $41,650 on the first day of each month after December
31, 1999 that the Company has not entered into a valid and
binding definitive agreement to license or sell its Acne Product;
provided, however, that no payment shall be due if such agreement
is not entered into by December 31, 2000.
(ii) $250,000 payable in shares of Parent Common Stock or
cash, in the case of the Minority Stockholders, if the Company
has Commercialized its External Analgesic Product prior to
December 31, 1999. Thereafter, this amount shall decrease $10,000
on the first day of each month after December 31, 1999 that the
Company has not Commercialized its External Analgesic Product;
provided, however, that no payment shall be due if the External
Analgesic Product is not Commercialized by December 31, 2000.
(iii) $250,000 payable in shares of Parent Common Stock or
cash, in the case of the Minority Stockholders, if the Company
has Commercialized its Benzocaine Canker Sore Product prior to
December 31, 1999. Thereafter, this amount shall decrease by
$10,000 on the first day of each month after December 31, 1999
that the Company has not Commercialized its Benzocaine Canker
Sore Product; provided, however, that no payment shall be due if
the Benzocaine Canker Sore Product is not Commercialized by
December 31, 2000.
(iv) $250,000 payable in shares of Parent Common Stock or
cash, in the case of the Minority Stockholders, if, and only if,
the Company has Commercialized its Topical Antibiotic Product
prior to December 31, 2000.
(v) $250,000 payable in shares of Parent Common Stock or
cash, in the case of the Minority Stockholders, if, and only if,
the Company has Commercialized its Wound Wash Product prior to
December 31, 2000.
(vi) the following consideration payable in shares of Parent
Common Stock or cash, in the case of the Minority Stockholders:
(A) $600,000 if the Company receives or has recognized,
in accordance with GAAP, an aggregate of $1,500,000 in any
payments (other than payments for reimbursed research and
development expenses or royalty fees) with respect to any
products relating to or based upon Company Intellectual
Property (collectively, "Product Revenue") after the Closing
Date and on or prior to December 31, 1999 ; and
(B) an additional $200,000 if the Company receives or
has recognized in accordance with GAAP an aggregate of
$2,000,000 in Product Revenue after the Closing Date and on
or prior to December 31, 1999; and
12
<PAGE> 17
(C) an additional $200,000 if the Company
receives or has recognized in accordance with GAAP an
aggregate of $2,500,000 in Product Revenue after the
Closing Date and on or prior to December 31, 1999.
In addition, as of December 31, 1999, or as soon as
practicable thereafter, Parent shall determine all Product
Revenue received or recognized by the Company, in accordance with
GAAP, on any products relating to or based upon Company
Intellectual Property as of such date and Parent shall pay to the
Stockholders additional consideration payable in Parent Common
Stock equal to the Product Revenue in excess of $1,500,000 or
$2,000,000, as the case may be, multiplied by 40%.
Notwithstanding the above, if the Company subsequently does not
receive any previously recognized Product Revenue then the future
payments related to Product Revenue to be made to the
Stockholders, if any, will be reduced by an amount equal to the
amount paid to the Stockholders for such Product Revenue not
actually received by the Company and, provided, further, that if
no future payments are payable to the Stockholders under this
Section 2.05(b), the Stockholders shall promptly reimburse Parent
upon notice for their pro rata portion of such excess payments
previously paid to the Stockholders.
(c) Parent Common Stock Payable to Each Principal Stockholder.
The number of shares of Parent Common Stock each Principal Stockholder
shall be entitled to receive shall be determined as follows:
(i) For the Parent Common Stock issuable under subsection
2.05(a), each Principal Stockholder shall receive shares of
Parent Common Stock equal to the product of (x) the Closing
Exchange Ratio times (y) the number of shares of Company Common
Stock held of record by such Principal Stockholder immediately
prior to the Effective Time. For purposes of this subsection
(c)(i), the "Closing Exchange Ratio" shall mean a number equal to
the quotient obtained by dividing (x) $500,000, by (y) the
average closing sale price of Parent Common Stock as reported on
the Nasdaq National Market for the twenty (20) consecutive
trading days ending three (3) business days prior to the Closing
Date, and dividing such quotient by (z) the Total Outstanding
Shares (Schedule 2.05(c)(i) sets forth (A) the Closing Exchange
Ratio and the Exchange Ratio, (B) the average closing sale price
of Parent Common Stock as reported on the Nasdaq National Market
for the twenty (20) consecutive trading days ending three (3)
business days prior to the Closing Date, and (C) the Total
Outstanding Shares);
(ii) For the Parent Common Stock issuable upon satisfaction
of the conditions set forth in subsections 2.05(b)(iv) and
2.05(b)(v), each Principal Stockholder shall receive shares of
Parent Common Stock equal to the product of (x) the
13
<PAGE> 18
Exchange Ratio times (y) the number of shares of Company Common
Stock held of record by such Principal Stockholder plus the
number of shares of Company Common Stock underlying an Assumed
Option held by such Principal Stockholder, immediately prior to
the Effective Time. For purposes of this subsection (c)(ii), the
"Exchange Ratio" shall mean, with respect to each Earn-Out Event
referenced in this subsection (c)(ii), a number equal to the
quotient obtained by dividing (x) the dollar amount payable in
Parent Common Stock under such Earn-Out Event, by (y) the average
closing sale price of Parent Common Stock as reported on the
Nasdaq National Market for the twenty (20) consecutive trading
days ending three (3) business days prior to the Closing Date,
and dividing such quotient by (z) the Total Outstanding Shares;
and (iii) For the shares of Parent Common Stock issuable pursuant
to subsections 2.05(b)(i), 2.05(b)(ii), 2.05(b)
(iii) and 2.05(b)(vi), each Principal Stockholder shall
receive shares of Parent Common Stock equal to the product of (x)
the Contingent Exchange Ratio times (y) the number of shares of
Company Common Stock held of record by such Principal Stockholder
plus the number of shares of Company Common Stock underlying an
Assumed Option held by such Principal Stockholder, immediately
prior to the Effective Time. For purposes of this subsection
(c)(iii), the "Contingent Exchange Ratio" shall mean, with
respect to each Earn-Out Event referenced in this subsection
(c)(iii), a number equal to the quotient obtained by dividing (x)
the dollar amount payable in Parent Common Stock under such
Earn-Out Event by (y) the average closing sale price of Parent
Common Stock as reported on the Nasdaq National Market for the
twenty (20) consecutive trading days ending on the last trading
day of the month in which the conditions to such Earn-Out Event
is satisfied, and dividing such quotient by (z) the Total
Outstanding Shares.
(d) Cash Payable to Stockholder(s).
(i) Minority Stockholders.
(A) In lieu of receiving shares of Parent Common Stock
under subsections 2.05(a) and 2.05(b)(i), 2.05(b)(ii),
2.05(b)(iii) and 2.05(b)(vi), each Minority Stockholder
shall receive cash in an amount equal to its Pro Rata
Portion of the portion of the Merger Consideration to be
paid pursuant to each such section less the aggregate option
exercise price, if applicable; provided, however, that a
Minority Stockholder's Pro Rata Portion shall include shares
of Company Common Stock underlying Assumed Options held by
such Minority Stockholder, with respect to Earn-Out Event
payments, but not otherwise.
(B) In lieu of receiving shares of Parent Common Stock
under subsections 2.05(b)(iv) and 2.05(b)(v), each Minority
Stockholder shall receive cash in an amount equal to (x) its
Pro Rata Portion of the portion of the Merger Consideration
14
<PAGE> 19
to be paid pursuant to each such section, divided by (y) the
average closing sale price of Parent Common Stock as
reported on the Nasdaq National Market for the twenty (20)
consecutive trading days ending three (3) business days
prior to the Closing Date, multiplied by (z) the average
closing sale price of Parent Common Stock as reported on the
Nasdaq National Market for the twenty (20) consecutive
trading days ending on the last trading day of the month in
which the conditions to such Earn-Out Event is satisfied;
provided, however, that a Minority Stockholder's Pro Rata
Portion shall include shares of Company Common Stock
underlying Assumed Options held by such Minority
Stockholder, with respect to Earn-Out Event payments, but
not otherwise.
(ii) Principal Stockholders. Each Principal Stockholder
shall receive cash in an amount equal to the product of such
Principal Stockholder's Pro Rata Portion multiplied by the
sum of (x) the Cash Payment Amount less (y) the aggregate
exercise price of each Cash-Out Option held by Principal
Stockholder, if applicable. Notwithstanding the foregoing,
the Cash Payment Amount otherwise payable to the Principal
Stockholders shall be reduced by the Escrow Amount in the
manner set forth in Section 2.07 herein.
(e) Development Obligations. Parent shall use and shall
cause the Company to use commercially reasonable and diligent
efforts to (i) license or sell the Acne Product by December 31,
1999, (ii) develop and commercialize (either directly or
indirectly) each of the External Analgesic Product and the
Benzocaine Canker Sore Product prior to December 31, 1999 and
(iii) develop and commercialize each of the Topical Antibiotic
Product and the Wound Wash Product by December 31, 2000. Any
license, sale or development or commercialization agreements
entered into by Parent or the Company with respect to the
foregoing shall be done on commercially reasonable terms. As used
herein, the term "commercially reasonable and diligent efforts"
will mean, unless the Stockholders' Representatives and the
Company otherwise agree in writing following the Closing, those
efforts consistent with the exercise of prudent scientific and
business judgment, as applied to other products of similar
potential and market size. Without limiting the generality of the
foregoing, "commercially reasonable and diligent efforts" shall
include the dedication of adequate business development resources
to licensing or selling the Acne Product and adequate
development, regulatory, sales and marketing and other resources
for commercializing new products. If Parent decides to abandon
efforts to license or sell the Acne Product for any reason other
than unanticipated changes in regulatory affairs, product failure
or changes in market conditions that make licensing or sale
infeasible or impractical or if Parent directly or through an
Affiliate elects to pursue commercialization of the Acne Product,
then the Earn-Out Event in subsection 2.05(b)(i) shall be deemed
to have occurred and, for purposes of Section 2.05(b)(vi), the
Company shall be deemed to have received $1,000,000 for purposes
of calculating Product Revenue. The Stockholders'
15
<PAGE> 20
Representatives, or their representatives including an
independent accounting firm, shall be entitled to request,
inspect and copy no more than once in any three month period
(provided, however, that such three month limitation shall not
apply if the Stockholders' Representatives have reasonable cause
to believe that Parent or the Company have failed to comply with
terms and provisions applicable to an Earn-Out Event) and subject
to reasonable notice and at reasonable times, Parent's or the
Company's records relating to their efforts to cause the Earn-Out
Events to occur and the amounts due to the Stockholders under
Section 2.05(b). All such inspections shall be conducted at the
Stockholders' expense and are subject to compliance by the
Stockholders' Representatives, and their representatives, with
the confidentiality provisions set forth in the Investment
Letter. In the event that it was determined that the amounts owed
to the Stockholders under Section 2.05(b) is greater than 5% of
the amounts actually paid to the Stockholders under Section
2.05(b), Parent shall pay the reasonable fees, costs and expenses
of such inspections. Any dispute with respect to the amount of
the payments to be made to the Stockholders under Section 2.05(b)
will be submitted to arbitration in accordance with Section 7.10.
Section 2.06. PAYMENT OF MERGER CONSIDERATION.
The Merger Consideration shall be due and payable as follows:
(a) Initial Payment. The Aggregate Initial Payment shall be due
and payable on the Closing Date in the manner set forth in Section
2.05. The Cash Payment Amount shall be paid by certified or official
bank check in immediately available funds to the order of the
applicable Stockholder or at the option of the Stockholder by wire
transfer of immediately available funds to an account or accounts to
be designated by such Stockholder to the Exchange Agent.
(b) Principal Stockholders' Contingent Consideration.
(i) Upon the satisfaction of an Earn-Out Event contained in
subsections 2.05(b)(i), (ii), (iii) or (vi), the Company shall
issue or cause to be issued to each Principal Stockholder a
certificate for the number of shares of Parent Common Stock to
which such Principal Stockholder is entitled under this Agreement
within five business days after the last day of the month in
which the condition for such Earn-Out Event is satisfied.
(ii) On the Closing Date, Parent shall deliver the Parent
Common Stock payable upon satisfaction of the Earn-Out Events
contained in subsections 2.05(b)(iv) or 2.05(b)(v) (the "Escrow
Shares") (using the same price per share used to calculate the
Exchange Ratio in subsection 2.05(c)(ii)) to an escrow agent
("Contingent Escrow Agent") to be held in escrow in accordance
with the terms hereof and the terms of the escrow agreements
attached hereto as Exhibit E (the "Contingent Escrow Agreement").
Upon the satisfaction of an Earn-Out Event contained in
subsections 2.05(b)(iv) or (v), the Company shall cause the
Contingent Escrow Agent to issue to each Principal Stockholder a
certificate for the number of shares of Parent Common Stock to
which such Principal Stockholder is entitled under this
Agreement, within five business days after the last day of the
month in which the condition for such Earn-Out Event is
satisfied.
16
<PAGE> 21
(iii) A Principal Stockholder may assign its right to
receive shares of Parent Common Stock under this subsection
2.06(b) to another Person or Persons provided the Principal
Stockholder and such Person or Persons (a "Permitted Assignee")
have executed an assignment and transfer agreement in the form
attached hereto as Exhibit P (the "Assignment and Transfer
Agreement").
(c) Minority Stockholders' Contingent Consideration. Upon the
satisfaction of an Earn-Out Event contained in subsection 2.05(b) the
Company shall pay to each Minority Stockholder the cash consideration
to which each such Minority Stockholder is entitled under this
Agreement by certified or official bank check in immediately available
funds to the order of the applicable Minority Stockholder or at the
option of the Minority Stockholder by wire transfer of immediately
available funds to an account or accounts designated by such Minority
Stockholder to Parent at the Closing, payable at the time the shares
of Parent Common Stock are payable to the Principle Stockholders under
such Earn-Out Event.
Section 2.07. ESCROW DEPOSIT.
Notwithstanding anything to the contrary contained in this Agreement,
Parent shall withhold an aggregate of ten percent (10%) of the Aggregate Initial
Payment from the Cash Payment Amount otherwise payable to the Principal
Stockholders (the "Escrow Amount") pursuant to Article II hereof, and deposit
the Escrow Amount into an interest bearing account (the "Escrow"), to be
governed by the terms hereof and the terms of the indemnity and escrow agreement
attached hereto as Exhibit F (the "Indemnity and Escrow Agreement") and the
escrow agent designated therein (the "Escrow Agent"). The indemnification
obligations of Parent and the Principal Stockholders for a breach of the
representations, warranties and covenants of the respective parties under this
Agreement and any Related Agreements are contained in the Indemnity and Escrow
Agreement.
Section 2.08. DISSENTING SHARES.
(a) Notwithstanding any provision of this Agreement to the
contrary, any shares of Company Capital Stock held by a holder who has
exercised and perfected appraisal rights to such shares in accordance
with Delaware Law and who, as of the Effective Time, has not
effectively withdrawn or lost such appraisal rights ("Dissenting
Shares"), shall not be converted into or represent a right to receive
the consideration for Company Capital Stock pursuant to Section 2.05,
but the holder thereof shall only be entitled to such rights as are
granted by Delaware Law.
(b) Notwithstanding the provisions of subsection (a), if any
holder of Dissenting Shares shall effectively withdraw or lose
(through failure to perfect or otherwise) his or her appraisal rights,
then, as of the later of the Effective Time or the occurrence of such
event, such holder's shares shall automatically be converted into and
represent only the right to receive the consideration for Company
Capital Stock as provided in Section 2.05, without interest thereupon,
upon surrender of the certificate representing such shares.
17
<PAGE> 22
(c) The Company shall give Parent (i) prompt notice of any
written demand for appraisal received by the Company pursuant to the
applicable provisions of Delaware Law, and (ii) the opportunity to
participate in all negotiations and proceedings with respect to such
demands. The Company shall not, except with the prior written consent
of Parent, make any payment with respect to any such demands or offer
to settle or settle any such demands. To the extent that Parent or the
Company makes any payment or payments in respect of any Dissenting
Shares, Parent shall be entitled to recover under the terms of Article
IX hereof the aggregate amount by which such payment or payments
exceed the aggregate consideration that otherwise would have been
payable in respect of such shares.
Section 2.09. NO FURTHER OWNERSHIP RIGHTS IN COMPANY CAPITAL STOCK.
The Merger Consideration payable under Section 2.05 for the surrender
for exchange of the Company Capital Stock in accordance with the terms hereof,
shall be deemed to be full satisfaction of all rights pertaining to such shares
of Company Capital Stock other than the right to participate in the Earn-Out
payments, if any, and there shall be no further registration of transfers on the
records of the Surviving Corporation of shares of Company Capital Stock which
were outstanding immediately prior to the Effective Time. If, after the
Effective Time, Company Stock Certificates are presented to the Surviving
Corporation for any reason, they shall be canceled and exchanged as provided in
this Article II.
Section 2.10. LOST, STOLEN OR DESTROYED CERTIFICATES.
In the event any certificates evidencing shares of Company Capital
Stock shall have been lost, stolen or destroyed, Parent shall issue in exchange
for such lost, stolen or destroyed certificates, upon the making of an affidavit
of that fact by the holder thereof, the Merger Consideration, if any, as may be
required pursuant to Section 2.05 herein; provided, however, that Parent may, in
its discretion and as a condition precedent to the issuance thereof, require the
Stockholder who is the owner of such lost, stolen or destroyed certificates to
deliver a bond in such sum, not to exceed such Stockholder's Pro Rata Portion of
the Merger Consideration, as it may reasonably direct against any claim that may
be made against Parent with respect to the certificates alleged to have been
lost, stolen or destroyed.
Section 2.11. FRACTIONAL SHARES.
Parent shall not be required to issue any fractional shares. In lieu of
issuing such fractional shares, Parent shall pay to each Stockholder to which
such fractional shares would otherwise be issuable, an amount in cash equal to
the product of the fractional share otherwise issuable multiplied by the average
sale price per share of Parent Common Stock as determined under Section 2.05(c)
herein.
Section 2.12. NO LIABILITY.
Notwithstanding anything to the contrary in this Article II, none of
the Parent, the Surviving Corporation or any party hereto shall be liable to a
holder of shares of Company Capital Stock for any amount properly paid to a
public official pursuant to any applicable abandoned property, escheat or
similar law.
18
<PAGE> 23
Section 2.13. CLOSING DELIVERIES.
At the Closing the parties to this Agreement shall deliver or cause to
be delivered the following documents and agreements:
(a) The Company shall deliver to Parent:
(i) a copy of this Agreement, duly and validly executed by
an executive officer of the Company;
(ii) a copy of the Indemnity and Escrow Agreement, duly and
validly executed by the Principal Stockholders;
(iii) a copy of the Contingent Escrow Agreement duly and
validly executed by the Principal Stockholders;
(iv) all consents, waivers, approvals and assignments listed
on Schedule 3.06 of the Disclosure Schedule;
(v) a legal opinion from Cooley Godward LLP, dated as of the
Closing Date, in the form of Exhibit H hereto;
(vi) Non-Competition Agreements in the form attached hereto
as Exhibit J executed by the persons listed on Exhibit I hereto;
(vii) Personal Service Agreements executed by each of the
persons listed on Exhibit K and as set forth therein;
(viii) Consent to Conversion of Preferred Stock executed by
all holders of Preferred Stock;
(ix) a certificate, dated as of the Closing Date, executed
on behalf of the Company by its Chief Executive Officer in the
form of Exhibit L attached hereto;
(x) Certificate of Merger duly and validly executed by an
executive officer of the Company; and
(xi) an Investment Letter executed by each of the Principal
Stockholders.
(b) Parent shall deliver to the Company and for the Stockholders
as appropriate:
(i) a copy of this Agreement, duly and validly executed by
an executive officer of the Company;
19
<PAGE> 24
(ii) a certificate, dated as of the Closing Date, executed
on behalf of Parent by its Chief Executive Officer or Chief
Financial Officer in substantially the form attached hereto as
Exhibit N;
(iii) a legal opinion from Morrison & Foerster LLP, legal
counsel to Parent, dated as of the Closing Date substantially in
the form of Exhibit O hereto;
(iv) a copy of the Indemnity and Escrow Agreement, duly and
validly executed by an executive officer of Parent; and
(v) a copy of the Contingent Escrow Agreement, duly and
validly executed by an executive officer of Parent.
(c) Parent shall deliver to the Exchange Agent or Escrow Agent,
as appropriate, cash and shares of Parent Common Stock in accordance
with the terms and provisions contained in this Article II.
Section 2.14. TAKING OF NECESSARY ACTION; FURTHER ACTION.
If at any time after the Effective Time, any further action is
necessary or desirable to carry out the purposes of this Agreement and to vest
the Surviving Corporation with full right, title and possession to all assets,
property, rights, privileges, powers and franchises of the Company, Parent,
Merger Sub and the officers and directors of the Company, Parent and Merger Sub
are fully authorized in the name of their respective corporations or otherwise
to take, and will take, all such lawful and necessary action.
ARTICLE III
REPRESENTATIONS AND WARRANTIES OF THE COMPANY
The Company hereby represents and warrants to Parent and Merger Sub,
subject to such exceptions as are specifically disclosed in the disclosure
schedule supplied by the Company and the Principal Stockholders to Parent and
Merger Sub (the "Disclosure Schedule") and dated as of the date hereof, that on
the date hereof and as of the Effective Time as though made at the Effective
Time as follows:
Section 3.01. ORGANIZATION OF THE COMPANY.
The Company is a corporation duly organized, validly existing and in
good standing under the laws of the State of Delaware. The Company has the
corporate power to own its properties and to carry on its business as now being
conducted. The Company is duly qualified or licensed to do business and in good
standing as a foreign corporation in the State of Texas and each other
jurisdiction in which it conducts business, except where the failure to so
qualify will not cause a Material Adverse Effect on the Company. The Company has
delivered a true and correct copy of its Certificate of Incorporation and
Bylaws, as amended to date, to Parent. Section 3.01 of the Disclosure Schedule
lists the directors and officers of the Company. The operations now being
conducted by the Company have not been conducted under any other names other
than ViroTex Corporation or Viro-Tex Corporation.
20
<PAGE> 25
Section 3.02. SUBSIDIARIES.
The Company does not have, and has never had, any subsidiaries and does
not otherwise own, and has not otherwise owned, any shares in the capital of or
any interest in, or control, directly or indirectly, of any corporation,
partnership, association, joint venture or other business entity.
Section 3.03. COMPANY CAPITAL STRUCTURE.
(a) As of October 31, 1998, the authorized capital stock of the
Company consisted of 15,000,000 shares of authorized Company Common
Stock of which 667,997 shares were issued and outstanding and
10,000,000 shares of authorized preferred stock consisting of 350,000
shares of Series A Convertible Preferred Stock all of which are issued
and outstanding; 384,616 shares of Series B Convertible Preferred
Stock all of which were issued and outstanding; 340,000 shares of
Series C Convertible Preferred Stock all of which were issued and
outstanding; 1,000,000 shares of Series D Convertible Preferred Stock
all of which were issued and outstanding; 1,566,668 shares of Series E
Convertible Preferred Stock all of which were issued and outstanding;
and 3,900,000 shares of Series F Convertible Preferred Stock of which
1,100,000 shares were issued and outstanding; and 2,458,716 shares of
undesignated preferred stock none of which was issued and outstanding.
All outstanding shares of Company Capital Stock as of October 31, 1998
were duly authorized, validly issued, fully paid and nonassessable and
not subject to preemptive rights created by statute, the Certificate
of Incorporation or Bylaws of the Company or any agreement to which
the Company was a party or by which it was bound and were issued in
compliance with federal and state securities laws. The Company has no
other Company Capital Stock authorized, issued or outstanding.
(b) As of the date hereof, there are 5,958,242 shares of Company
Common Stock outstanding. The Company Common Stock is held by the
persons with the domicile addresses and in the amounts set forth in
Section 3.03(b) of the Disclosure Schedule. All unexercised Cash-Out
Options that were outstanding as of October 31, 1998 have been
exercised or, to the extent not exercised, will be assumed by Parent
at Closing, and if exercised the holders of the Cash-Out Options have
executed the form of option exercise ("Option Exercise Notice")
attached hereto as Exhibit T. As of the date hereof, each of the
holders of Preferred Stock have executed a "Consent to Conversion of
Preferred Stock" in the form of Exhibit Q, each of which consents are
in full force and effect and have not been revoked. All outstanding
shares of Company Common Stock are duly authorized, validly issued,
fully paid and nonassessable and not subject to preemptive rights
created by statute, the Certificate of Incorporation or Bylaws of the
Company or any agreement to which the Company is a party or by which
it is bound and have been issued in compliance with federal and state
securities laws. There are no declared or accrued unpaid dividends
with respect to any shares of Company Capital Stock. The Company has
no other Company Capital Stock authorized, issued or outstanding.
21
<PAGE> 26
(c) Except for the Company's 1991 Stock Option Plan, as amended
(the "Plan"), the Company has never adopted or maintained any stock
option plan or other plan providing for equity compensation of any
person. The Company has reserved 1,575,000 shares of Company Common
Stock for issuance to directors, employees, consultants and attorneys
pursuant to the Plan, of which, as of the date hereof, 1,559,781
shares have been issued and 983,000 shares are subject to outstanding
Assumed Options. Section 3.03(c) of the Disclosure Schedule sets forth
for each Assumed Option, the name of the holder of such Assumed
Option, the domicile address of such holder, the number of shares of
Company Common Stock subject to such Assumed Option, the exercise
price of such Assumed Option, the vesting schedule for such Assumed
Option, including the extent vested to date and whether the vesting of
such Assumed Option will be accelerated by the transactions
contemplated by this Agreement, and whether such Assumed Option is
intended to qualify as an incentive stock option as defined in Section
422 of the Code. Section 3.03(c) of the Disclosure Schedule also sets
forth the name of the holder of any Company Capital Stock subject to
vesting, the number of shares of Company Capital Stock subject to
vesting and the vesting schedule for such Company Capital Stock,
including the extent vested to date and whether the vesting of such
shares of Company Capital Stock will be accelerated by the
transactions contemplated by this Agreement. Except for the Assumed
Options and the GulfStar Warrant, there are no options, warrants,
calls, rights, commitments or agreements of any character, written or
oral, to which the Company is a party or by which it is bound
obligating the Company to issue, deliver, sell, repurchase or redeem,
or cause to be issued, delivered, sold, repurchased or redeemed, any
shares of Company Capital Stock or obligating the Company to grant,
extend, accelerate the vesting of, change the price of, otherwise
amend or enter into any such option, warrant, call, right, commitment
or agreement. There are no outstanding or authorized stock
appreciation, phantom stock, profit participation, or other similar
rights with respect to Company Capital Stock. Other than the
appointment of the Stockholders' Representatives as contemplated in
the Indemnity and Escrow Agreement, there are no voting trusts,
proxies, or other agreements or understandings with respect to the
voting stock of the Company.
Section 3.04. AUTHORITY.
The Company has all requisite power and authority to enter into this
Agreement and any Related Agreements to which it is a party and to consummate
the transactions contemplated hereby and thereby. The execution and delivery of
this Agreement and any Related Agreements to which the Company is a party and
the consummation of the transactions contemplated hereby and thereby have been
duly authorized by all necessary corporate action on the part of the Company,
and no further action is required on the part of the Company to authorize the
Agreement and any Related Agreements to which it is a party and the transactions
contemplated hereby and thereby. Stockholders holding at least ninety-five
percent (95%) of the Company Capital Stock have approved this Agreement, the
22
<PAGE> 27
Merger and the transactions contemplated hereby and thereby. This Agreement and
any Related Agreements to which the Company is a party have been duly executed
and delivered by the Company and, assuming the due authorization, execution and
delivery by the other parties hereto, constitutes the valid and binding
obligation of the Company, enforceable in accordance with its terms, except as
such enforceability may be limited by principles of public policy and subject to
the laws of general application relating to bankruptcy, insolvency and the
relief of debtors and to rules of law governing specific performance, injunctive
relief or other equitable remedies.
Section 3.05. NO CONFLICT.
The execution and delivery by the Company of this Agreement and any
Related Agreement to which the Company is a party and the consummation of the
transactions contemplated hereby and thereby will not conflict with or result in
any violation of or default under (with or without notice or lapse of time, or
both) or give rise to a right of termination, cancellation, modification or
acceleration of any obligation or loss of any benefit under (any such event, a
"Conflict") (i) any provision of the Certificate of Incorporation and Bylaws of
the Company, (ii) any mortgage, indenture, lease, contract or other agreement or
instrument, permit, concession, franchise or license to which the Company or any
of its properties or assets is subject, or (iii) any judgment, order, decree,
statute, law, ordinance, rule or regulation applicable to the Company or its
properties or assets.
Section 3.06. CONSENTS.
No consent, waiver, approval, order or authorization of, or
registration, declaration or filing with any court, administrative agency or
commission or other federal, state, county, local or other foreign governmental
authority, instrumentality, agency or commission ("Governmental Entity") or any
third party, including a party to any agreement with the Company (so as not to
trigger any Conflict), is required by or with respect to the Company in
connection with the execution and delivery of this Agreement and any Related
Agreement to which the Company is a party or the consummation of the
transactions contemplated hereby and thereby, except for such consents, waivers,
approvals, orders, authorizations, registrations, declarations and filings as
may be required under applicable securities laws hereby and thereby and filing
of the Certificate of Merger. The Company has obtained all consents, waivers and
approvals under any of the Contracts deemed reasonably appropriate or necessary
by Parent in connection with the Merger (all of such consents, waivers and
approvals are set forth in Section 3.06 of the Disclosure Schedule) so as to
preserve all rights of, and benefits to, the Company thereunder.
Section 3.07. COMPANY FINANCIAL STATEMENTS.
The Company has delivered to Parent the Company's audited balance
sheets as of December 31, 1997 and 1996, and related audited statements of
income, cash flow and stockholders' equity for the fiscal years then ended (the
"Year-End Financials") and (ii) the Company's unaudited balance sheet as of
September 30, 1998, and related unaudited statements of income, cash flow and
shareholders' equity for the three months and the nine months then ended (the
"Interim Financials"). The Year-End Financials and the Interim Financials are
correct in all material respects and have been prepared in accordance with GAAP
23
<PAGE> 28
(except that the Interim Financials do not contain all footnotes and other
presentation items that may be required by GAAP). The Year-End Financials and
Interim Financials present fairly the financial condition, operating results and
cash flows of the Company as of the dates and during the periods indicated
therein, subject, in the case of the Interim Financials, to normal year-end
adjustments, which will not be material in amount or significance.
Section 3.08. NO UNDISCLOSED LIABILITIES.
The Company has no liability, indebtedness, obligation, expense, claim,
deficiency, guaranty or endorsement of any type, whether accrued, absolute,
contingent, matured, unmatured or other (whether or not required to be reflected
in financial statements in accordance with GAAP), which individually or in the
aggregate (i) has not been reflected in or reserved against in the Current
Balance Sheet, or (ii) has not arisen in the ordinary course of business
consistent with past practices prior to or subsequent to September 30, 1998, in
either case which amounts exceed $25,000 in the aggregate; provided, however,
all liabilities for accrued but unpaid vacation or time off for employees or
other benefits or liabilities payable to such employees upon termination of
employment have been accrued and reflected on the Current Balance Sheet and, in
any event, total severance benefits payable to the Company's employees and
former employees shall not exceed $425,000.00 at the Closing Date.
Section 3.09. PRODUCTS/PRODUCT LIABILITY.
(a) Each of the products produced, developed or sold by the
Company (excluding products developed by the Company but produced and
sold by third parties under license or agreement or by third parties
to which such products were sold, provided, that the Company has been
fully indemnified by such third parties for any and all liabilities
relating thereto, which indemnification rights will continue in full
force and effect after the Effective Time) (the "Company Products")
is, and at all times up to and including the sale thereof by the
Company has been (a) in compliance in all material respects with all
applicable federal, state, and local laws and regulations, and (b)
conforms in all material respects to any promises or affirmations of
fact made on the container or label for such product or in connection
with its sale.
(b) To the knowledge of the Company, there is no design defect
with respect to the Company Products. At the time of sale to the
public, each Company Product contained adequate warnings, presented in
a reasonably prominent manner, in accordance with applicable laws,
rules and regulations and current industry practice with respect to
its contents and use.
(c) The Company's External Analgesic Product, Benzocaine Canker
Sore Product, Topical Antibiotic Product, Wound Wash Product, Wart
Removal Product and BEMA-Dyclonine Canker Sore Disc (if such product
is launched in the OTC market), as currently formulated, satisfy and
conform and will satisfy and conform with (i) each OTC drug monograph
applicable to such products and their intended uses, as promulgated by
the Food and Drug Administration ("FDA"), (ii) the active ingredients
allowed by the applicable OTC monographs both as to the specified
concentration established for each ingredient and as to the specified
24
<PAGE> 29
dosage form set forth in the applicable OTC monograph or, if no dosage
or concentration is specified, in amounts and forms that conform to
current industry standards. Such products, excluding the
BEMA-Dyclonine Canker Sore Disk if not launched in the OTC market,
will not require the filing of a new drug application with the FDA
under current laws and regulations.
(d) The Company has no knowledge of any liability, or of any
facts or circumstances reasonably likely to give rise to any
litigation against the Company, arising out of or relating to any
injury to individuals or property as a result of the ownership,
possession, or use of any product developed, manufactured or sold by
the Company. The Company has provided the Parent with true and correct
copies of its standard product warranties, and all Contracts to which
it is a party, performance of which by the Company has not been
completed, and which include nonstandard product warranties.
Section 3.10. LOANS, NOTES, CASH, ACCOUNTS RECEIVABLE AND ACCOUNTS PAYABLE.
The Company has provided Parent with an accurate and complete breakdown
and aging of all accounts receivable, notes receivable and other receivables of
the Company as of the Balance Sheet Date. All receivables (a) have arisen only
from bona fide transactions in the ordinary course of business consistent with
past practice, (b) represent valid obligations, and (c) are current and are
expected to be collectible in the aggregate face amounts thereof without any
counterclaim or set-off when due, except to the extent of the normal allowance
for doubtful accounts with respect to accounts receivable that are computed in a
manner consistent with GAAP and as reflected in the Balance Sheet or with
respect to receivables arising subsequent to the Balance Sheet Date, the books
and records of the Company, and (d) are owned by the Company free of all Liens.
No discount or allowance from any receivable has been made or agreed to (other
than customary payment discounts in the ordinary course of business consistent
with past practice), and none represents billings prior to actual sale of goods
or provision of services. Accounts payable of the Company reflected on the
Balance Sheet and all accounts payable arising after the Balance Sheet Date
arose, and have arisen, from bona fide transactions. The Company has $1,000,000
in cash after deducting the Company Payment Amount. The Company has paid all
costs and obligations customarily paid by the Company through the date hereof in
accordance with past practice.
Section 3.11. PROJECTIONS.
The financial projections relating to the Company products identified
in Section 3.16(h) (excluding the Wart Removal Product and BEMA-Dyclonine Canker
Sore Disc) and delivered to Parent as set forth in Exhibit G hereto, were made
in good faith and are based upon assumptions that the Company believes were
reasonable, and the Company is not aware of any fact or set of circumstances
that would lead it to believe that such projections are incorrect or misleading
in any material respect.
25
<PAGE> 30
Section 3.12. ABSENCE OF CERTAIN CHANGES.
Since the Balance Sheet Date, the Company has conducted its business in
the ordinary course consistent with past practices and, except pursuant to or as
contemplated under this Agreement or any Related Agreements, there has not been
any Material Adverse Effect and there is no condition or development or
contingency of any kind existing that could reasonably be expected to result in
a Material Adverse Effect on the business of the Company. Without limiting the
foregoing, except as set forth in Section 3.12 of the Disclosure Schedule, since
the Balance Sheet Date, there has not been, occurred or arisen:
(a) any issuance or sale or authorization of the issuance or sale
of any shares of Company Capital Stock or other securities of the
Company or options or warrants relating to shares of Company Capital
Stock or other securities of the Company;
(b) any declaration, setting aside or payment of any dividend or
other distribution with respect to any shares of Company Capital
Stock, or any direct or indirect repurchase, redemption, retirement,
purchase or other acquisition by the Company of any outstanding shares
of capital stock or other securities of, or other ownership interests
in, the Company;
(c) any amendment of any material term of any outstanding
security of the Company;
(d) any incurrence, assumption or guarantee by the Company of any
indebtedness for borrowed money, other than in the ordinary course of
business, exceeding $10,000;
(e) any creation or assumption by the Company of any Lien on any
material asset of the Company;
(f) any making of any loan, advance or capital contributions to
or investment in any Person;
(g) any material damage, destruction or other casualty loss
affecting the business or assets of the Company not covered by
insurance;
(h) any transaction or commitment made, or any contract or
agreement entered into, by the Company relating to its assets or
business (including the acquisition or disposition of any assets) or
any relinquishment by the Company of any contract or other right
(direct or indirect, whether alleged, contingent or otherwise), in
either case, material to the Company, taken as a whole;
(i) any sale, assignment, transfer or grant of any license or
sublicense with respect to any Intellectual Property Right or other
intangible asset used or useful in the business of the Company;
26
<PAGE> 31
(j) any incurrence or payment of any material obligation or
liability (absolute, accrued or contingent) other than current
liabilities shown on the Balance Sheet and current liabilities
incurred since the Balance Sheet Date in the ordinary course of
business consistent with past practice;
(k) any change in any method of accounting or accounting practice
by the Company, except for any such change after the date hereof
required by reason of a concurrent change in GAAP;
(l) any (i) employment, deferred compensation, severance,
retirement or other similar agreement entered into with any director,
officer or employee of the Company (or any amendment to any such
existing agreement), (ii) grant of any severance or termination pay to
any director, officer or employee of the Company, or (iii) change in
compensation or other benefits payable to any director, officer or
employee of the Company pursuant to any severance or retirement plans
or policies thereof;
(m) any labor dispute, other than routine individual grievances,
or any activity or proceeding by a labor union or representative
thereof to organize any employees of the Company, which employees were
not subject to a collective bargaining agreement at the Balance Sheet
Date, or any lockouts, strikes, slowdowns, work stoppages or threats
thereof by or with respect to any employees of the Company;
(n) any tax election by the Company or any settlement or
compromise of any income tax liability by the Company;
(o) any other material occurrence, event, incident, action,
failure to act, or transaction outside the ordinary course of business
involving the Company; and
(p) the Company has not committed to any of the foregoing.
Section 3.13. TAX MATTERS.
(a) Definitions. For purposes of this Agreement, the following
definitions shall apply:
(i) The term "Taxes" shall mean all taxes, however,
denominated, including any interest, penalties or other additions
to tax that may become payable in respect thereof, imposed by any
federal, territorial, state, local or foreign government or any
agency or political subdivision of any such government, which
taxes shall include, without limiting the generality of the
foregoing, all income or profits (including, but not limited to,
federal income taxes and state income taxes), payroll and
employee withholding, social security, sales and use, ad valorem,
excise, franchise, gross receipts, business license, occupation,
real and personal property, stamp, environmental, transfer,
workers' compensation and any other taxes, tariffs or
governmental charges, and other obligations of the same or of a
similar nature to any of the foregoing, which the Company is
required to pay, withhold or collect.
27
<PAGE> 32
(ii) The term "Returns" shall mean all reports, estimates,
declarations of estimated tax, information statements and returns
relating to, or required to be filed in connection with, any
Taxes, including information returns or reports with respect to
backup withholding and other payments to third parties.
(b) Returns Filed and Taxes Paid. All Returns required to be
filed by or on behalf of the Company have been duly filed on a timely
basis, or requests for extensions to file such Returns have been
timely filed, granted and have not expired, and such Returns are true,
complete and correct in all material respects. All material Taxes due
with respect to periods ending on or prior to the Closing Date,
whether or not required to be shown on a Return to be due, have been
or will be paid in full on a timely basis. The Company has withheld
and paid over all Taxes required to have been withheld and paid over,
and complied with all information reporting and backup withholding
requirements, including maintenance of required records with respect
thereto, in connection with amounts paid or owing to any employee,
creditor, independent contractor, or other third party. There are no
liens on any of the assets of the Company with respect to Taxes, other
than liens for Taxes not yet due and payable or for Taxes that the
Company is contesting in good faith through appropriate proceedings
and for which appropriate reserves have been established.
(c) Tax Reserves. The reserves for Taxes reflected on the Current
Balance Sheet are adequate for the payment of all Taxes payable by the
Company for all taxable periods and portions thereof accrued through
the date of the Current Balance Sheet, and such reserves will continue
to be established in accordance with past practice with respect to
Taxes payable for any taxable period or portion thereof ending on or
prior to the Closing Date.
(d) Returns Furnished. The Company has made available to Parent
true and complete copies of (i) relevant portions of income tax audit
reports, statements of deficiencies, closing or other similar
agreements received by or on behalf of the Company relating to Taxes
and (ii) all federal and state income or franchise tax returns for the
Company for all periods ending on or after December 31, 1995. The
Company has never been a member of an affiliated group filing
consolidated returns. The Company does not do business in or derive
income from any state, local, territorial or foreign taxing
jurisdiction other than those for which all Returns have been
furnished to Parent.
(e) Tax Deficiencies; Audits; Statutes of Limitations. The
Returns of the Company have never been audited by a government or
taxing authority, nor, to the knowledge of the Company, is any such
audit in process, pending or threatened. No deficiencies exist or have
been asserted or, to the Company's knowledge, are expected to be
asserted with respect to Taxes of the Company, and the Company has not
28
<PAGE> 33
received and does not expect to receive notice that it has not filed a
Return or paid Taxes required to be filed or paid by it. There is no
action or proceeding pending for the assessment or collection of Taxes
to which the Company is a party, nor has such an action been asserted
or threatened against the Company or any of its assets. No waiver or
extension of any statute of limitations is in effect with respect to
Taxes or Returns of the Company.
(f) Tax Sharing Agreements. The Company is not and has never been
a party to any agreement providing for sharing, indemnification or
allocation of Taxes, whether formal or informal.
(g) Tax Elections and Special Tax Status. The Company is not a
party to any safe harbor lease within the meaning of Section 168(f)(8)
of the Code, as in effect prior to amendment by the Tax Equity and
Fiscal Responsibility Act of 1982. The Company is not, and has not
been at any time during the five year period ending on the Closing
Date, a United States real property holding corporation within the
meaning of Section 897(c)(2) of the Code. The Company has not given a
consent under Section 341(f) of the Code. The Company will not be
required to include in a taxable period ending after the Closing Date
taxable income attributable to income that economically accrued in a
taxable period ending on or prior to the Closing Date as a result of
the installment method of accounting, the completed contract method of
accounting, the cash method of accounting or otherwise. The Company
has not agreed, nor is it required, to make any adjustment under Code
Section 481(a) by reason of a change in accounting method or
otherwise. The Company has not participated in an international
boycott as defined in Code Section 999. The Company does not have a
permanent establishment in any foreign country, as defined in any
applicable Tax treaty or convention between the United States of
America and such foreign country, and the Company is not a party to
any joint venture, partnership or other agreement, contract or
arrangement (either in writing or verbally, formally or informally)
which could be treated as a partnership for federal income tax
purposes.
(h) Tax Basis and Tax Attributes. The Company Tax Return for the
1997 fiscal year, contained, to the extent required to be included,
accurate and complete descriptions of the Company's tax basis in its
assets, current and accumulated earnings and profits, tax carryovers,
and tax elections affecting the Company. The Company has no net
operating losses or other tax attributes presently subject to
limitation under Code Sections 382, 383, or 384.
(i) Compensation. The disallowance of a deduction under Section
162(m) of the Code will not apply to any amount paid or payable by the
Company under any contract, stock plan, benefit plan, program,
arrangement or understanding currently in effect. Any amount or other
entitlement that could be received as a result of any of the
transactions contemplated by this Agreement by any employee, officer
or director of the Company under any employment, severance or
termination agreement, other compensation arrangement or benefit plan
currently in effect would not be characterized as an "excess parachute
payment" (as such term is defined in Section 280G(b)(1) of the Code).
29
<PAGE> 34
Section 3.14. RESTRICTIONS ON BUSINESS ACTIVITIES.
There is no agreement (non-compete or otherwise), commitment, judgment,
injunction, order or decree to which the Company is a party or otherwise binding
upon the Company which has or may reasonably be expected to have the effect of
prohibiting or impairing any business practice of the Company, any transfer of
property (tangible or intangible) by the Company or the conduct of business by
the Company. Without limiting the foregoing, the Company has not entered into
any agreement under which the Company is restricted from selling, licensing or
otherwise distributing any of its technology or products to or providing
services to, customers or potential customers or any class of customers, in any
geographic area, during any period of time or in any segment of the market.
Section 3.15. TITLE OF PROPERTIES; ABSENCE OF LIENS AND ENCUMBRANCES;
CONDITION OF EQUIPMENT.
(a) The Company does not own any real property and has never
owned any real property. Section 3.15(a) of the Disclosure Schedule
sets forth a list of all real property currently leased by the
Company, the name of the lessor, the date of the lease and each
amendment thereto and, with respect to any current lease, the
aggregate annual rental and/or other fees payable under any such
lease. All such current leases are in full force and effect, are valid
and effective in accordance with their respective terms, and there is
not, under any of such leases, any existing default or event of
default (or event which with notice or lapse of time, or both, would
constitute a default)
(b) The Company has good and valid title to, or, in the case of
leased properties and assets, valid leasehold interests in, all of its
tangible properties and assets, real, personal and mixed, used or held
for use in its business, free and clear of any Liens, except (i) as
reflected in the Current Balance Sheet, (ii) Liens for Taxes not yet
due and payable and (iii) landlord Liens.
(c) Section 3.15(c) of the Disclosure Schedule lists all items of
equipment (the "Equipment") owned or leased by the Company and such
Equipment is (i) adequate for the conduct of the business of the
Company as currently conducted and (ii) in good operating condition,
regularly and properly maintained, subject to normal wear and tear.
(d) The Company has sole and exclusive ownership, free and clear
of any Liens, of all customer files and other customer information
relating to the Company's current and former customers (the "Customer
Information"), except to the extent that such customers have rights of
access to their own Customer Information. No person other than the
Company possesses any claims or rights with respect to use of the
Customer Information.
30
<PAGE> 35
Section 3.16. INTELLECTUAL PROPERTY.
(a) For the purposes of this Agreement, the following terms have
the following definitions:
(i) "Intellectual Property" shall mean any or all of the
following and all rights in, arising out of, or associated
therewith: (A) all United States and foreign patents and
applications therefor and all reissues, divisions, renewals,
extensions, provisionals, continuations and continuations-in-part
thereof; (B) all inventions (whether patentable or not),
invention disclosures, improvements, trade secrets, proprietary
information, know how, technology, technical data and customer
lists, and all documentation relating to any of the foregoing;
(C) all copyrights, copyright registrations and applications
therefor and all other rights corresponding thereto throughout
the world; (D) all mask works, mask work registrations and
applications therefor, (E) all industrial designs and any
registrations and applications therefor throughout the world; (F)
all trade names, logos, common law trademarks and service marks;
trademark and service mark registrations and applications
therefor and all goodwill associated therewith throughout the
world; (G) all databases and data collections and all rights
therein throughout the world; (H) all computer software including
all source code, object code, firmware, development tools, files,
records and data, all media on which any of the foregoing is
recorded, all Web addresses, sites and domain names, (I) any
similar, corresponding or equivalent rights to any of the
foregoing and (J) all documentation related to any of the
foregoing.
(ii) "Company Intellectual Property" shall mean any
Intellectual Property that is owned by or exclusively licensed to
the Company.
(iii) "Registered Intellectual Property" shall mean all
United States, international and foreign: (A) patents, patent
applications (including provisional applications); (B) registered
trademarks, applications to register trademarks, intent-to-use
applications, or other registrations or applications related to
trademarks; (C) registered copyrights and applications for
copyright registration; (D) any mask work registrations and
applications to register mask works; and (E) any other Company
Intellectual Property that is the subject of an application,
certificate, filing, registration or other document issued by,
filed with, or recorded by, any state, government or other public
legal authority.
(b) Section 3.16(b) of the Disclosure Schedule lists all
Registered Intellectual Property owned by, or filed in the name of,
the Company (the "Company Registered Intellectual Property"), and
lists any proceedings or actions before any court, tribunal (including
the United States Patent and Trademark Office (the "PTO") or
equivalent authority anywhere in the world) related to any of the
Company Registered Intellectual Property.
31
<PAGE> 36
(c) Each item of Company Intellectual Property is free and clear
of any Liens. The Company (i) is the exclusive owner of all trademarks
and trade names used in connection with the operation or conduct of
the business of the Company, including the sale of any products or
technology or the provision of any services by the Company, and (ii)
owns exclusively, and has good title to, all copyrighted works that
are Company products or other works of authorship that the Company
otherwise purports to own.
(d) To the extent that any Intellectual Property has been
developed or created by any person other than the Company for which
the Company has, directly or indirectly, paid, the Company has a
written agreement with such person with respect thereto and the
Company thereby has the right to become the owner of or to obtain an
exclusive license with respect to all such Intellectual Property by
operation of law or by valid assignment.
(e) To the knowledge of the Company, any non-proprietary software
used by the Company (other than commercially available off the shelf
software), is free from significant programming errors and operates in
substantial conformity with its user documentation and other
descriptions and standards applicable thereto provided by the Company,
and such software does not contain any known virus, timer, clock,
counter or other limiting design, instruction or routine, that would
erase data, programming or become inoperable or otherwise incapable of
being used in the full manner for which it was designed and created
nor has the Company been informed that the non-proprietary software
has any such problems.
(f) The licenses, sublicenses, agreements, contracts and
permissions (as amended to date) listed in Schedule 3.16(f) include
all licenses, sublicenses, agreements, contracts and permissions with
respect to any Intellectual Property licensed to or used by the
Company. With respect to each such license, sublicense, agreement,
contract or permission:
(i) the license, sublicense, agreement, or permission
covering the item is legal, valid, binding, enforceable, and in
full force and effect;
(ii) the license, sublicense, agreement, or permission will
continue to be legal, valid, binding, enforceable, and in full
force and effect on identical terms following the Effective Date;
(iii) to the Company's knowledge (other than with respect to
the Company), no party to the license, sublicense, agreement, or
permission is in breach or default, and no event has occurred
which with notice or lapse of time would constitute a breach or
default or permit termination, modification, or acceleration
thereunder;
(iv) to the Company's knowledge (other than with respect to
the Company), no party to the license, sublicense, agreement, or
permission has repudiated any provision thereof;
32
<PAGE> 37
(v) to the Company's knowledge (other than with respect to
Company Intellectual Property), the underlying item of the
Intellectual Property is not subject to any outstanding judgment,
order, decree, stipulation, injunction, or charge; and
(vi) to the Company's knowledge (other than with respect to
Company Intellectual Property), no charge, complaint, action,
suit, proceeding, hearing, investigation, claim, or demand is
pending, or to the knowledge of the Company (including, employees
with responsibility for Intellectual Property matters) is
threatened, which challenges the legality, validity, or
enforceability of the underlying item of the Intellectual
Property.
(g) Except as set forth in Section 3.16(g), the Company has not
transferred ownership of or granted any license of or right to use or
authorized the retention of any rights to use any Intellectual
Property that is or was Company Intellectual Property, to any other
person.
(h) The Company Intellectual Property constitutes all the
Intellectual Property used in or reasonably necessary to the conduct
of its business as it currently is conducted, and, to the Company's
knowledge, as is currently contemplated to be conducted with respect
to the Acne Product, External Analgesic Product, Benzocaine Canker
Sore Product, Topical Antibiotic Product, Wound Wash Product, Wart
Removal Product, BEMA-Dyclonine Canker Sore Disc, BEMA-Dyclonine
Strips and BEMA-Nicotine, including, without limitation, the design,
development, manufacture, use, import and sale of such products,
technology or services.
(i) Section 3.16(i) of the Disclosure Schedule lists all
contracts, licenses and agreements between the Company and any other
person (other than off the shelf software) wherein or whereby the
Company has agreed to, or assumed, any obligation or duty to warrant,
indemnify, reimburse, hold harmless, guaranty or otherwise assume or
incur any obligation or liability or provide a right of rescission
with respect to the infringement or misappropriation by the Company or
such other person of the Intellectual Property of any person other
than the Company.
(j) To the Company's knowledge, the operation of the business of
the Company as it currently is conducted or is currently contemplated
to be conducted with respect to the Acne Product, External Analgesic
Product, Benzocaine Canker Sore Product, Topical Antibiotic Product,
Wound Wash Product, Wart Removal Product, BEMA-Dyclonine Canker Sore
Disc, BEMA-Dyclonine Strips and BEMA-Nicotine, including but not
limited to the Company's design, development, use, import, manufacture
and sale of such products, technology or services does not infringe or
misappropriate the Intellectual Property of any person, violate the
rights of any person (including rights to privacy or publicity), or
constitute unfair competition or trade practices under the laws of any
jurisdiction, and the Company has not received notice from any person
claiming that such operation or any act, product, technology or
33
<PAGE> 38
service (including products, technology or services currently under
development) of the Company infringes or misappropriates the
Intellectual Property of any person or constitutes unfair competition
or trade practices under the laws of any jurisdiction (nor is the
Company aware of any basis therefor).
(k) All necessary registration, maintenance and renewal fees in
connection with the Company Registered Intellectual Property have been
paid and all necessary documents and certificates in connection with
the Company Registered Intellectual Property have been filed with the
relevant patent, copyright, trademark or other authorities in the
United States or foreign jurisdictions, as the case may be, for the
purposes of maintaining such Registered Intellectual Property. Except
as set forth in Section 3.16(k)) of the Disclosure Schedule, there are
no actions that must be taken by the Company within sixty (60) days of
the Closing Date, including the payment of any registration,
maintenance or renewal fees or the filing of any documents,
applications or certificates for the purposes of maintaining,
perfecting or preserving or renewing any Company Intellectual
Property. Except as set forth in Section 3.16(k) of the Disclosure
Schedule, for each product or technology of the Company that
constitutes or includes a copyrightable work, the Company has
registered the copyright in the latest version of such work with the
U.S. Copyright Office. In each case in which the Company has acquired
any Company Registered Intellectual Property rights from any person,
the Company has obtained a valid and enforceable assignment sufficient
to irrevocably transfer all rights in such Company Registered
Intellectual Property (including the right to seek past and future
damages with respect to such Intellectual Property) to the Company
and, to the maximum extent provided for by, and in accordance with,
applicable laws and regulations, the Company has recorded each such
assignment with the relevant governmental authorities, including the
PTO, the U.S. Copyright Office, or their respective equivalents in any
relevant foreign jurisdiction, as the case may be.
(l) There are no contracts, licenses or agreements between the
Company and any other person with respect to Company Intellectual
Property under which there is any dispute known to the Company
regarding the scope of such agreement or performance under such
agreement including with respect to any payments to be made or
received by the Company thereunder.
(m) To the knowledge of the Company, no person is infringing or
misappropriating any Company Intellectual Property.
(n) The Company has taken all reasonable steps that are required
to protect the Company's rights in confidential information and trade
secrets of the Company or provided by any other person to the Company.
Without limiting the foregoing, the Company has, and enforces, a
policy requiring each employee, consultant and contractor to execute
proprietary information, confidentiality and assignment agreements
substantially in the Company's standard forms as set forth, in
Schedule 3.16(n), and all current and former employees, consultants
and contractors of the Company have executed such an agreement. To the
Company's knowledge, no employee of the Company is subject to any
secrecy or noncompetition agreement or any agreement or restriction of
34
<PAGE> 39
any kind that would impede in any material way the ability of such
employee to carry out fully all activities of such employee in
furtherance of the business of the Company as currently operated after
the Closing Date. To the Company's knowledge, no third party has
claimed that any person employed by or affiliated with the Company has
violated or may be violating any of the terms or conditions of his
past employment, noncompetition or nondisclosure agreement with such
third party; or disclosed or may be disclosing or utilized or may be
utilizing any trade secret or proprietary information or documentation
of such third party or interfered or may be interfering in the
employment relationship between such third party and any of its
present or former employees.
(o) No Company Intellectual Property or product, technology or
service of the Company is subject to any proceeding or outstanding
decree, order, judgment, agreement or stipulation that restricts in
any manner the use, transfer or licensing thereof by the Company or
may affect the validity, use or enforceability of such Company
Intellectual Property.
(p) No (i) product, technology, service or publication of the
Company (ii) material published or distributed by the Company or (iii)
conduct or statement of the Company constitutes obscene material, a
defamatory statement or material, false advertising or otherwise
violates any law or regulation, except where any such violation will
not have a Material Adverse Effect on the Company.
(q) All material software products used by the Company (other
than off the shelf software) will record, store, process, calculate
and present calendar dates falling on and after (and if applicable,
spans of time including) January 1, 2000, and will calculate any
information dependent on or relating to such dates in the same manner,
and with the same functionality, data integrity and performance, as
the products record, store, process, calculate and present calendar
dates on or before December 31, 1999, or calculate any information
dependent on or relating to such dates.
Section 3.17. AGREEMENTS, CONTRACTS AND COMMITMENTS.
(a) Except as set forth in Section 3.17(a) of the Disclosure
Schedule, the Company is not a party to nor is it bound by:
(i) any employment or consulting agreement, contract or
commitment with an employee or individual consultant or
salesperson or consulting or sales agreement, contract or
commitment with a firm or other organization;
(ii) any agreement or plan, including, without limitation,
any stock option plan, stock appreciation rights plan or stock
purchase plan, any of the benefits of which will be increased, or
the vesting of benefits of which will be accelerated, by the
occurrence of any of the transactions contemplated by this
Agreement or the value of any of the benefits of which will be
calculated on the basis of any of the transactions contemplated
by this Agreement;
35
<PAGE> 40
(iii) any fidelity or surety bond or completion bond;
(iv) any lease of personal property having a value in excess
of $10,000 individually or $25,000 in the aggregate;
(v) any agreement, contract or commitment containing any
covenant limiting the freedom of the Company to engage in any
line of business or to compete with any person,
(vi) any agreement, contract or commitment relating to
capital expenditures and involving future payments in excess of
$25,000 individually or $50,000 in the aggregate;
(vii) any agreement, contract or commitment relating to the
disposition or sale of assets or any interest in any business
enterprise outside the ordinary course of the Company's business;
(viii) any mortgages, indentures, loans or credit
agreements, security agreements or other agreements or
instruments relating to the borrowing of money or extension of
credit;
(ix) any purchase order or contract for the purchase of
materials involving in excess of $10,000 individually or $50,000
in the aggregate;
(x) any construction contracts;
(xi) any dealer, distribution, joint marketing or
development agreement;
(xii) any sales representative, original equipment
manufacturer, value added, remarketer or other agreement for
distribution of the Company's products or services;
(xiii) any written indemnification agreements between the
Company and its directors and officers other than indemnification
obligations set forth in the Company's Certificate of
Incorporation or Bylaws;
(xiv) any agreement granting a third-party a right of first
offer or right of first refusal for any products of the Company
or any products developed by the Company in the future; or
(xv) any other agreement, contract or commitment that
involves $25,000 individually or $50,000 in the aggregate or is
not cancelable without penalty within thirty (30) days.
(b) The Company is in compliance in all material respects with
and has not breached, violated or defaulted under, or received notice
that it has breached, violated or defaulted under, any of the terms or
conditions of any agreement, contract, covenant, instrument, lease,
36
<PAGE> 41
license or commitment to which the Company is a party or by which
either is bound (collectively a "Contract"), nor is the Company aware
of any event that would constitute such a breach, violation or default
with the lapse of time, giving of notice or both. Assuming due
execution by the other parties thereto, each Contract is in full force
and effect and the Company is not subject to any default thereunder,
nor to the knowledge of the Company is any party obligated to the
Company pursuant to such Contract subject to any default thereunder.
Following the Closing, the Company will be permitted to exercise all
of the Company's rights under the Contracts without the payment of any
additional amounts or consideration other than ongoing fees, royalties
or payments which the Company would otherwise be required to pay had
the transactions contemplated by this Agreement not occurred. The
Company has not received notice from CEP Holdings, Inc., or its
assignees, that it intends to curtail promoting, marketing or selling
the Viractin(R) product line.
Section 3.18. INTERESTED PARTY TRANSACTIONS.
No officer, director or Stockholder of the Company (nor, to the actual
knowledge of the Company, any ancestor, sibling, descendant or spouse of any of
such persons, or any trust, partnership or corporation in which any of such
persons has or has had an interest), has or has had, directly or indirectly, (i)
an interest in any entity that furnished or sold, or furnishes or sells,
services, products or technology that the Company furnishes or sells, or
proposes to furnish or sell, or (ii) any interest in any entity that purchases
from or sells or furnishes to the Company, any goods or services, or (iii) a
beneficial interest in any Contract; provided, that ownership of no more than
one percent (1%) of the outstanding voting stock of a publicly traded
corporation shall not be deemed to be an "interest in any entity" for purposes
of this Section 3.18.
Section 3.19. GOVERNMENTAL AUTHORIZATION.
Section 3.19 of the Disclosure Schedule accurately lists each consent,
license, permit, grant or other authorization issued to the Company by a
Governmental Entity (i) pursuant to which the Company currently operates or
holds any interest in any of its properties or (ii) which is required for the
operation of its business as currently conducted or the holding of any such
interest (herein collectively called "Company Authorizations"), except for any
immaterial authorizations. The Company Authorizations are in full force and
effect and constitute all Company Authorizations required to permit the Company
to operate or conduct its business as currently conducted or presently
contemplated or to hold any interest in its properties or assets, except for any
Authorizations that if not obtained would not have a Material Adverse Effect on
the Company.
Section 3.20. REGULATORY REPORTS.
The Company, and to the Company's knowledge, all licensees or
co-development partners of the Company, has filed all material reports,
registrations and statements, together with any amendments required to be made
with respect thereto, that they were required to file in respect to any drug
delivery product or other product developed by the Company (other than the
Viractin(R) product line since its sale to CEP Holdings, Inc.) (the "Products")
in the last five (5) year period with any federal, state, local or foreign
37
<PAGE> 42
governmental, quasi-governmental or regulatory department, authority or agency,
including, without limitation, the FDA or the Federal Trade Commission
(collectively, "Regulatory Agencies"), and has paid all fees or assessments due
and payable in connection therewith. No Regulatory Agency has initiated any
proceeding or investigation into the business or operations of the Company or
the Products in the last five (5) year period, nor has the Company or the
Company's licensee or co-development partners initiated any such proceeding.
There is no unresolved violation, criticism or exception by any Regulatory
Agency with respect to any report or statement relating to an examination of the
Products.
Section 3.21. LITIGATION.
There is no action, suit or proceeding of any nature pending, or, to
the Company's knowledge, threatened, against the Company its properties or any
of its officers or directors, nor, to the knowledge of the Company, is there any
reasonable basis therefor. There is no investigation pending or, to the
Company's knowledge, threatened, against the Company, its properties or any of
its officers or directors (nor, to the knowledge of the Company, is there any
reasonable basis therefor) by or before any Governmental Entity. No Governmental
Entity has at any time challenged or questioned the legal right of the Company
to conduct its operations as presently or previously conducted.
Section 3.22. MINUTE BOOKS.
The minutes of the Company made available to counsel for Parent are the
only minutes of the Company and contain summaries, accurate in all material
respects, of all meetings of the Board of Directors (or committees thereof) of
the Company and its shareholders or actions by written consent since the time of
incorporation of the Company.
Section 3.23. ENVIRONMENTAL MATTERS.
The Company is not in material violation of any Environmental Laws
applicable to it or its properties, or any material limitations, restrictions,
conditions, standards, obligations or timetables contained in any Environmental
Laws. No notice or action alleging such violation is pending or, to the
Company's knowledge, threatened, and no past or present condition or practice of
the businesses conducted by the Company would prevent continued compliance with
any Environmental Permits or give rise to any common law or statutory liability
or otherwise from the basis of any claim, action or proceeding with respect to
the Company involving any Hazardous Substances. The Company has no Environmental
Liability.
Section 3.24. BROKERS' AND FINDERS' FEES AND THIRD PARTY EXPENSES.
Except for a fee to be paid pursuant to the terms of an agreement dated
November 4, 1997 between the Company and to Volpe Brown Whelan & Company (the
"Volpe Agreement"), which will be paid by the Company at Closing (the "Volpe
Brown Fee"), the Company has not incurred, nor will it incur, directly or
indirectly, any liability for brokerage or finders' fees or agents' commissions
or any similar charges in connection with the Agreement or any transaction
contemplated hereby. The Company has terminated the Volpe Agreement. The Company
has provided Parent with a written statement of the Estimated Third Party
Expenses.
38
<PAGE> 43
Section 3.25. EMPLOYEE BENEFIT PLANS AND COMPENSATION.
(a) The following terms shall have the meanings set forth below:
(i) "Affiliate" for purposes of this Section 3.25, shall
mean any other person or entity under common control with the
Company within the meaning of Section 414(b), (c), (m) or (o) of
the Code and the regulations issued thereunder;
(ii) "Company Employee Plan" shall mean any plan, program,
policy, practice, contract, agreement or other arrangement
providing for compensation, severance, termination pay, deferred
compensation, performance awards, stock or stock-related awards,
fringe benefits or other employee benefits or remuneration of any
kind, whether written or unwritten, funded or unfunded, including
without limitation, each "employee benefit plan," within the
meaning of Section 3(3) of ERISA which is or has been maintained,
contributed to, or required to be contributed to, by the Company
or any Affiliate for the benefit of any Employee, or with respect
to which the Company or any Affiliate has or may have any
liability or obligation;
(iii) "COBRA" shall mean the Consolidated Omnibus Budget
Reconciliation Act of 1985, as amended;
(iv) "DOL" shall mean the Department of Labor;
(v) "Employee" shall mean any current or former employee,
consultant or director of the Company or any Affiliate;
(vi) "Employee Agreement" shall mean each management,
employment, severance, consulting, relocation or other agreement,
contract or understanding between the Company or any Affiliate
and any Employee;
(vii) "ERISA" shall mean the Employee Retirement Income
Security Act of 1974, as amended; and
(viii) "FMLA" shall mean the Family Medical Leave Act of
1993, as amended;
(ix) "IRS" shall mean the Internal Revenue Service;
(x) "PBGC" shall mean the Pension Benefit Guaranty
Corporation; and
(xi) "Pension Plan" shall mean each Company Employee Plan
which is an "employee pension benefit plan," within the meaning
of Section 3(2) of ERISA.
39
<PAGE> 44
(b) Schedule. Section 3.25(b) of the Disclosure Schedule contains
an accurate and complete list of each Company Employee Plan and each
Employee Agreement under each Company Employee Plan or Employee
Agreement. The Company does not have any plan or commitment to
establish any new Company Employee Plan or Employee Agreement, to
modify any Company Employee Plan or Employee Agreement (except to the
extent required by law or to conform any such Company Employee Plan or
Employee Agreement to the requirements of any applicable law, in each
case as previously disclosed to Parent in writing, or as required by
this Agreement), or to enter into any Company Employee Plan or
Employee Agreement.
(c) Termination of Employee Agreements. The Company has
terminated each of the Employee Agreements set forth on Schedule
3.25(c) and has received a release in full of any liability in
connection with such Employee Agreement, except with respect to the
payment of the severance obligations required under such Employee
Agreement, which obligations are set forth in the Disclosure Schedule.
The provisions of the Employee Agreements relating to confidentiality,
non-competition and invention assignment will continue in full force
and effect for the period of time set forth in each Employee
Agreement.
(d) Documents. The Company has provided to Parent: (i) correct
and complete copies of all documents embodying each Company Employee
Plan and each Employee Agreement including (without limitation) all
amendments thereto and all related trust documents; (ii) the three (3)
most recent annual reports (Form Series 5500 and all schedules and
financial statements attached thereto), if any, required under ERISA
or the Code in connection with each Company Employee Plan; (iii) if
the Company Employee Plan is funded, the most recent annual and
periodic accounting of Company Employee Plan assets; (iv) the most
recent summary plan description together with the summary(ies) of
material modifications thereto, if any, required under ERISA with
respect to each Company Employee Plan; (v) all material written
agreements and contracts relating to each Company Employee Plan,
including, but not limited to, administrative service agreements and
group insurance contracts; (vi) all communications material to any
Employee or Employees relating to any Company Employee Plan and any
proposed Company Employee Plans, in each case, relating to any
amendments, terminations, establishments, increases or decreases in
benefits, acceleration of payments or vesting schedules or other
events which would result in any liability to the Company; (vii) all
correspondence to or from any governmental agency directly relating to
any Company Employee Plan; (viii) all COBRA forms and related notices
currently in use by the Company or under which the Company is
currently obligated; (ix) all policies in force pertaining to
fiduciary liability insurance covering the fiduciaries for each
Company Employee Plan; (x) all discrimination tests for each Company
Employee Plan for the most recent plan year; and (xi) all registration
statements, annual reports (Form 10-K and all attachments thereto) and
prospectuses prepared in connection with each Company Employee Plan.
40
<PAGE> 45
(e) Employee Plan Compliance. (i) The Company has performed in
all material respects all obligations required to be performed by it
under, is not in default or violation of, and has no knowledge of any
default or violation by any other party to each Company Employee Plan,
and each Company Employee Plan has been established and maintained in
all material respects in accordance with its terms and in compliance
with all applicable laws, statutes, orders, rules and regulations,
including but not limited to ERISA or the Code; (ii) no "prohibited
transaction," within the meaning of Section 4975 of the Code or
Sections 406 and 407 of ERISA, and not otherwise exempt under Section
408 of ERISA, has occurred with respect to any Company Employee Plan;
(iii) there are no actions, suits or claims pending, or, to the
knowledge of the Company, threatened or reasonably anticipated (other
than routine claims for benefits) against any Company Employee Plan or
against the assets of any Company Employee Plan; (iv) each Company
Employee Plan can be amended, terminated or otherwise discontinued
after the Effective Time in accordance with its terms, without
liability to Parent, the Company or any Affiliate (other than ordinary
administration expenses); (v) there are no audits, inquiries or
proceedings pending or, to the knowledge of the Company or any
Affiliates, threatened by the IRS or DOL with respect to any Company
Employee Plan; and (vi) neither the Company nor any Affiliate is
subject to any penalty or tax with respect to any Company Employee
Plan under Section 502(i) of ERISA or Sections 4975 through 4980 of
the Code.
(f) No Pension Plans. Neither the Company nor any Affiliate has
ever maintained, established, sponsored, participated in, or
contributed to, any Pension Plan.
(g) No Post-Employment Obligations. No Company Employee Plan
provides, or reflects or represents any liability to provide, retiree
life insurance, retiree health or other retiree employee welfare
benefits to any person for any reason, except as may be required by
COBRA or other applicable statute or except for severance or other
benefits set forth in the Disclosure Schedule, and the Company has
never represented, promised or contracted (whether in oral or written
form) to any Employee (either individually or to Employees as a group)
or any other person that such Employee(s) or other person would be
provided with retiree life insurance, retiree health or other retiree
employee welfare benefit, except to the extent required by statute.
(h) COBRA. Neither the Company nor any Affiliate has, prior to
the Effective Time, violated any of the health care continuation
requirements of COBRA, the requirements of FMLA or any similar
provisions of state law applicable to its Employees.
(i) Effect of Transaction. The execution of this Agreement and
the consummation of the transactions contemplated hereby will not
(either alone or upon the occurrence of any additional or subsequent
events) constitute an event under any Company Employee Plan, Employee
Agreement, trust or loan that will or may result in any payment
(whether of severance pay or otherwise), acceleration, forgiveness of
indebtedness, vesting, distribution, increase in benefits or
obligation to fund benefits with respect to any Employee.
41
<PAGE> 46
(j) Employment Matters. Schedule 3.25(j) sets forth a true and
complete list of the names, title, annual salaries and other
compensation of all officers of the Company and all other employees of
the Company. The Company: (i) is in compliance with all applicable
foreign, federal, state and local laws, rules and regulations
respecting employment, employment practices, terms and conditions of
employment and wages and hours, in each case, with respect to
Employees, except where such noncompliance would not have a Material
Adverse Effect on the Company; provided, however, that Schedule
3.25(j) shall disclose any such laws, rules and regulations which, to
the Company's actual knowledge, it is not in compliance whether or not
material; (ii) is not liable for any arrears of wages or any penalty
for failure to comply with the foregoing; and (iii) is not overdue on
any payment to any trust or other fund governed by or maintained by or
on behalf of any governmental authority, with respect to unemployment
compensation benefits, social security or other benefits or
obligations for Employees (other than routine payments to be made in
the normal course of business and consistent with past practice).
There are no pending or, to the knowledge of the Company, threatened
or reasonably anticipated claims or actions against the Company under
any worker's compensation policy or long-term disability policy.
(k) Labor. No work stoppage or labor strike against the Company
is pending, or to the knowledge of the Company, threatened or
reasonably anticipated. The Company does not know of any activities or
proceedings of any labor union to organize any Employees. There are no
actions, suits, claims, labor disputes or grievances pending, or, to
the knowledge of the Company, threatened or reasonably anticipated
relating to any labor, safety or discrimination matters involving any
Employee, including, without limitation, charges of unfair labor
practices or discrimination complaints. Neither the Company nor any of
its subsidiaries has engaged in any unfair labor practices within the
meaning of the National Labor Relations Act. The Company is not
presently, nor has it been in the past, a party to, or bound by, any
collective bargaining agreement or union contract with respect to
Employees and no collective bargaining agreement is being negotiated
by the Company.
Section 3.26. INSURANCE.
Section 3.26 of the Disclosure Schedule lists all insurance policies
and fidelity bonds covering the assets, business, equipment, properties,
operations, employees, officers and directors of the Company or any Affiliate.
There is no claim by the Company or any Affiliate pending under any of such
policies or bonds as to which coverage has been questioned, denied or disputed
by the underwriters of such policies or bonds and the Company has made no claims
under such policies within the last five years. All premiums due and payable
under all such policies and bonds have been paid, and the Company and its
Affiliates are otherwise in material compliance with the terms of such policies
and bonds (or other policies and bonds providing substantially similar insurance
coverage). The Company does not have knowledge of any threatened termination of,
or premium increase with respect to, any of such policies.
42
<PAGE> 47
Section 3.27. COMPLIANCE WITH LAWS.
The Company has complied with, is not in violation of, and has not
received any notices of violation with respect to, any foreign, federal, state
or local statute, law or regulation, except where the failure to comply will not
have a Material Adverse Effect on the Company.
Section 3.28. WARRANTIES; INDEMNITIES.
Except as set forth in Section 3.28 of the Disclosure Schedule and
warranties implied by law, the Company has not given any warranties or
indemnities relating to products or technology developed, sold or services
rendered by the Company.
Section 3.29. CONFLICTS OF INTEREST.
None of the Company or any officer, employee, agent or other Person
acting on behalf of the Company has, directly or indirectly, given or agreed to
give any money, gift or similar benefit (other than legal price concessions to
customers in the ordinary course of business) to any customer, supplier,
employee or agent of a customer or supplier, or official or employee of any
Governmental Authority or other Person who was or is in a position to help or
hinder the business of the Company (or assist in connection with any actual or
proposed transaction) that (i) might subject the Company to any damage or
penalty in any proceeding or investigation, (ii) if not given in the past, could
have resulted in a Material Adverse Effect on the Company, or (iii) if not
continued in the future, could result in a Material Adverse Effect on the
Company.
Section 3.30. COMPLETE COPIES OF MATERIALS.
The Company has delivered or made available true and complete copies of
each document (or summaries of same) that has been requested specifically in
writing by Parent or its counsel.
Section 3.31. REPRESENTATIONS COMPLETE.
No representation or warranty made by the Company, nor any statement
made in the Disclosure Schedule or certificate furnished by the Company pursuant
to this Agreement or any Related Agreements contains or will contain, any untrue
statement of a material fact or omits or will omit to state any material fact
necessary in order to make the statements contained herein or therein not
misleading.
43
<PAGE> 48
ARTICLE IV
REPRESENTATIONS AND WARRANTIES OF PARENT AND MERGER SUB
Parent and Merger Sub hereby represent and warrant to the Company that
on the date hereof and as of the Effective Time as though made at the Effective
Time as follows:
Section 4.01. ORGANIZATION, STANDING AND POWER.
Parent is a corporation duly organized, validly existing and in good
standing under the laws of the State of Delaware. Merger Sub is a corporation
duly organized, validly existing and in good standing under the laws of
Delaware. Each of Parent and Merger Sub has the corporate power to own its
properties and to carry on its business as now being conducted and is duly
qualified or licensed to do business and is in good standing in each
jurisdiction in which the failure to be so qualified or licensed would have a
material adverse effect on the ability of Parent and Merger Sub to consummate
the transactions contemplated hereby.
Section 4.02. AUTHORITY.
Each of Parent and Merger Sub has all requisite corporate power and
authority to enter into this Agreement and any Related Agreements to which it is
a party and to consummate the transactions contemplated hereby and thereby. The
execution and delivery of this Agreement and any Related Agreements to which it
is a party and the consummation of the transactions contemplated hereby and
thereby will be duly authorized by all necessary corporate action on the part of
Parent and Merger Sub at and as of the Closing Date. This Agreement and any
Related Agreements to which Parent and Merger Sub are parties have been duly
executed and delivered by Parent and Merger Sub and, assuming the due
authorization, execution and delivery by the other parties hereto, constitute
the valid and binding obligations of Parent and Merger Sub, enforceable in
accordance with their terms, except as such enforceability may be limited by
principles of public policy and subject to the laws of general application
relating to bankruptcy, insolvency and the relief of debtors and rules of law
governing specific performance, injunctive relief or other equitable remedies.
Section 4.03. BROKERS' AND FINDERS FEES.
Neither Parent nor Merger Sub has incurred, nor will it incur, directly
or indirectly, any liability for brokerage or finders' fees or agents'
commissions or any similar charges in connection with this Agreement or any
transaction contemplated hereby.
Section 4.04. NO CONFLICT.
The execution and delivery of this Agreement and any Related Agreements
to which it is a party and, the consummation of the transactions contemplated
hereby will not Conflict with or give rise to a Conflict under (i) any provision
of the Certificate of Incorporation, as amended, and Bylaws of Parent or Merger
Sub, (ii) any mortgage, indenture, lease, contract or other agreement or
instrument, permit, concession, franchise or license to which Parent or any of
its respective properties or assets are subject and which has been filed as an
44
<PAGE> 49
exhibit to Parent's filings under the Securities Act or the Exchange Act, or
(iii) any judgment, order, decree, statute, law, ordinance, rule or regulation
applicable to Parent or Merger Sub or its properties or assets, except where
such Conflict will not have a Material Adverse Effect on the business, assets
(including intangible assets), financial condition or results of operations of
Parent and Merger Sub taken as a whole.
Section 4.05. CONSENTS.
No consent, waiver, approval, order or authorization of, or
registration, declaration or filing with, any Governmental Entity, or any third
party is required by or with respect to Parent or Merger Sub in connection with
the execution and delivery of this Agreement and any Related Agreements to which
Parent or Merger Sub is a party or the consummation of the transactions
contemplated hereby or thereby, except for such consents, waivers, approvals,
orders, authorizations, registrations, declarations and filings as may be
required under applicable securities laws hereby or thereby and such consents,
waivers, approvals, orders, authorizations, registrations, declarations and
filings which, if not obtained or made, would not have a Material Adverse Effect
on the business, assets (including intangible assets), financial condition or
results of operations of Parent and its subsidiaries taken as a whole.
Section 4.06. COMPLIANCE WITH LAWS.
Parent has complied with, is not in violation of, and has not received
any notices of violation with respect to, any foreign, federal, state or local
statute, law or regulation, except where the failure to comply will not have a
Material Adverse Effect on Parent.
Section 4.07. SEC REPORTS.
The Parent's Annual Report on Form 10-K for the year ended December 31,
1997 and each form, report, schedule, registration statement and definitive
proxy statement filed by Parent with the SEC subsequent thereto (as such
documents have been amended prior to the date hereof, the "Parent SEC Reports"),
as of their respective dates, complied in all material respects with the
applicable requirements of the Securities Act and the Exchange Act and the rules
and regulations thereunder. None of the Parent SEC Reports, as of their
respective dates, contained or contains any untrue statement of material fact or
omits to state a material fact required to be stated therein or necessary to
make the statements therein, in light of the circumstances under which they were
made, not misleading. The financial statements of Parent included in such
reports comply as to form in all material respects with applicable accounting
requirements and with the published rules and regulations of the SEC with
respect thereto, have been prepared in accordance with GAAP (except as may be
indicated in the notes to such financial statements and, in the case of
unaudited statements, as permitted by Form 10-Q of the SEC, and except that
unaudited financial statements may not contain footnotes and are subject to
year-end audit adjustments) and fairly present the financial position of Parent
as and at the date thereof and the results of its operations and cash flows for
the periods then ended. Since December 31, 1997, neither Parent nor any of its
subsidiaries has incurred any liabilities or obligations of any nature (whether
absolute, accrued, fixed, contingent, liquidated or unliquidated, known or
45
<PAGE> 50
unknown) except liabilities, obligations and contingencies (a) which are
reflected in the consolidated balance sheet of Parent at December 31, 1997, or
(b) which (i) were incurred in the ordinary course of business since December
31, 1997 and consistent with past practices, (ii) are disclosed in the Parent
SEC Reports filed since December 31, 1997, or (iii) would not individually or in
the aggregate have a Material Adverse Effect on Parent. Since December 31, 1997,
except as described in any Parent SEC Reports, there has been no change in any
of the significant accounting policies, practices or procedures of Parent except
changes resulting from changes in accounting pronouncements of the Financial
Accounting Standards Boards or changes in applicable laws. Parent has timely
filed all SEC Reports required to be filed by Parent and is eligible to register
shares for resale on Form S-3.
Section 4.08. FINANCIAL CAPABILITY.
Parent will have on the Closing Date and immediately prior to the
Effective Time, funds and authorized and unissued shares of Parent Common Stock
sufficient to consummate the Merger, fund the escrow for the earn-out and
otherwise consummate the transactions contemplated hereby.
Section 4.09. PARENT CAPITAL STRUCTURE.
(a) As of the date hereof, the authorized capital stock of the
Parent consists of 25,000,000 shares of authorized Parent Common Stock
of which 11,322,560 shares are issued and outstanding; and 5,000,000
shares of authorized preferred stock consisting of 200,000 shares
designated as Series A Preferred Stock none of which is issued and
outstanding; and 4,800,000 shares of undesignated preferred stock none
of which is issued and outstanding. All outstanding shares of Parent
Common Stock are duly authorized, validly issued, fully paid and
nonassessable. Parent has reserved 2,631,578 shares of Parent Common
Stock for issuance upon conversion of Parent's Subordinated
Convertible Notes due 2004. The Parent has also reserved 300,000
shares of Parent Common Stock for issuance to employees of Parent
pursuant to the Parent's 1997 Employee Stock Purchase Plan, of which
7,708 shares have been issued. The Parent has no other Parent Capital
Stock authorized, issued or outstanding.
(b) The Parent has reserved 2,500,000 shares of Parent Common
Stock for issuance to officers, directors and key employees, employees
of Parent and subsidiaries of Parent pursuant to Parent's Amended and
Restated Performance Stock Option Plan, of which, as of the date
hereof, 731,965 shares have been issued, and 1,136,904 shares are
subject to outstanding, unexercised options. The Parent has reserved
150,000 shares of Parent Common Stock for issuance to non-employees of
Parent pursuant to the Parent's Nonqualified Stock Option Plan, of
which, as of the date hereof, 43,500 shares have been issued and
34,480 shares are subject to outstanding, exercised options.
46
<PAGE> 51
ARTICLE V
ADDITIONAL AGREEMENTS
Section 5.01. EXPENSES.
Whether or not the Merger is consummated, all fees and expenses
incurred in connection with the Merger including, without limitation, all legal,
accounting, financial advisory, consulting and all other fees and expenses of
third parties ("Third Party Expenses") incurred by a party in connection with
the negotiation and effectuation of the terms and conditions of this Agreement
and the transactions contemplated hereby or thereby, shall be the obligation of
the respective party incurring such fees and expenses; provided, that, if the
Merger is consummated, Parent and the Company agree that the Company will pay
the Volpe Brown Fee, all accounting fees incurred by the Company and up to
$50,000 of additional Third Party Expenses incurred by the Company (the "Company
Payment Amount"), and the Stockholders shall pay all Third Party Expenses in
excess of the Company Payment Amount through a reduction of the cash paid at
Closing.
Section 5.02. PUBLIC DISCLOSURE.
Unless otherwise required by law, no disclosure (whether or not in
response to an inquiry) of the subject matter of this Agreement shall be made by
any party hereto unless approved by the other parties hereto prior to release.
Section 5.03. S-8 REGISTRATION.
In the event Parent's current Registration Statement on Form S-8 does
not contain a sufficient number of shares to cover the shares of the Parent
Common Stock issuable upon exercise of the Assumed Options, promptly after the
Closing Date, Parent shall prepare and file with the Securities and Exchange
Commission an amendment to Parent's Registration Statement on Form S-8 (or
another appropriate form) to register the necessary number of shares of Parent
Common Stock subject to Assumed Options.
Section 5.04. REGISTRATION STATEMENT.
(a) Within ten (10) business days after the Closing Date, Parent
shall file a registration statement on Form S-3 (the "Registration
Statement") to cover the resale of the shares of Parent Common Stock
issued or to be issued to the Stockholders pursuant to the terms of
this Agreement, including, without limitation, all shares of Parent
Common Stock issuable upon the occurrence of an Earn-Out Event, the
Parent Warrant and shares of Parent Common Stock issuable upon
exercise of the Parent Warrant (the "Registered Shares"). Parent shall
use its best efforts to cause such Registration Statement to be
declared effective within sixty (60) days after the filing date.
Parent shall use its best efforts to keep such Registration Statement
continuously effective, supplemented and amended for a period of two
years after the Closing Date. For purposes of this Section 5.04 and
Section 5.05 the term "Stockholders" shall include Permitted
Assignees.
47
<PAGE> 52
(b) Parent will bear the costs of all Registration Expenses. For
the purposes hereof, "Registration Expenses" shall mean all expenses
incident to Parent's preparation and filing of the Registration
Statement, including, without limitation, all registration and filing
fees, fees and expenses of compliance with federal securities laws or
state blue sky laws, printing expenses, messenger and delivery
expenses, fees and disbursements of custodians and fees and
disbursements of counsel for Parent and all independent certified
public accountants, and other persons retained by Parent (but not of
Stockholder's counsel).
Section 5.05. REGISTRATION PROCEDURES.
In connection with the registration and sale of the Registered Shares
the Company will:
(a) prepare and file with the Commission the Registration
Statement as set forth above;
(b) provide to each Stockholder a copy of the Registration
Statement and related Prospectus, including each preliminary
Prospectus, if any, and each amendment and supplement thereto;
(c) use its best efforts to register or qualify the Registered
Shares under such other securities or blue sky laws of such
jurisdictions as each Stockholder may reasonably request and do any
and all other acts and things that may be reasonably necessary or
advisable to enable such Stockholder to consummate the disposition in
such jurisdictions of the Registered Shares owned by such Stockholder;
provided, however, that Parent will not be required to (i) qualify
generally to do business in any jurisdiction where it would not
otherwise be required to qualify but for this subsection (c), (ii)
subject itself to taxation in any such jurisdiction, or (iii) consent
to general service of process in any such jurisdiction;
(d) Upon the occurrence of any event that would cause the
Registration Statement (i) to contain any untrue statement of a
material fact or omit to state a material fact required to be stated
therein or necessary to make the statements therein not misleading or
(ii) to be not effective and useable for resale of the Registered
Shares during the period that such Registration Statement is required
to be effective and useable, Parent upon knowledge of such an event,
shall as promptly as practicable file an amendment to the Registration
Statement, in the case of clause (i), correcting any such misstatement
or omission, and, in the case of either clause (i) or (ii), use its
best efforts to cause such amendment to be declared effective and such
Registration Statement to become useable as soon as practicable
thereafter;
(e) Notwithstanding anything to the contrary in this Section
5.05, Parent may prohibit offers and sales of the Registered Shares
pursuant to the Registration Statement at any time if (A) (i) it is in
possession of material non-public information, (ii) the Board of
Directors of Parent determines based on advice of counsel (which
counsel shall be experienced in securities laws matters) that such
prohibition is necessary in order to avoid a requirement to disclose
48
<PAGE> 53
such material non-public information, and (iii) the Board of Directors
of Parent determines in good faith that disclosure of such material
non-public information would not be in the best interests of Parent
and its stockholders, or (B) (i) Parent has made a public announcement
relating to an acquisition or business combination transaction
including Parent and/or one or more of its subsidiaries that is
material to Parent and its subsidiaries taken as a whole, and (ii) the
Board of Directors of Parent determines in good faith that offers and
sales of the Registered Shares pursuant to the Registration Statement
prior to the consummation of such transaction (or such earlier date as
the Board of Directors shall determine) is not in the best interests
of Parent and its stockholders (the period during which any such
prohibition of offers and sales of Registered Shares pursuant to the
Registration Statement is in effect pursuant to clause (A) or (B) of
this subsection 5.05(e) is referred to herein as a "Suspension
Period"); provided, however, that the Suspension Period may not occur
any more frequently than once in any twelve month period. A Suspension
Period shall commence on and include the date on which Parent provides
written notice to Stockholders covered by the Registration Statement
that offers and sales of Registered Shares cannot be made thereunder
in accordance with this Section 5.05 and shall end three Business Days
after the earlier to occur of (x) the date on which such material
information is disclosed to the public or ceases to be material or
Parent is able to so comply with its disclosure obligations and
Commission requirements, or (y) 45 days after written notice is
provided by Parent to the Stockholders of such Suspension Period. Each
notice shall state to the extent, if any, as is practicable, an
estimate of the expected duration of the Suspension Period;
(f) Parent shall provide to each Stockholder a copy of the
proposed plan of distribution to be included in the Registration
Statement and each Stockholder shall furnish to Parent such
information regarding the distribution of its Registered Shares as is
required by law to be disclosed in the Registration Statement (the
"Requisite Information") prior to effecting any sale pursuant to such
Registration Statement. Each Stockholder as to which any Registration
Statement is being effected agrees prior to effecting any sale of the
Registered Shares thereunder to furnish promptly to Parent all
information required to be disclosed in order to make any Requisite
Information previously furnished to Parent by such Stockholder not
materially misleading or necessary to cause such Registration
Statement not to omit a material fact with respect to such Stockholder
necessary in order to make the statements therein not misleading;
(g) Each Stockholder agrees by acquisition of such Registered
Shares that, upon receipt of any notice from Parent of the existence
of any fact of the kind described in subsections 5.05(d) and (e)
hereof (an "Amendment Notice"), such Stockholder will forthwith
discontinue disposition of Registered Shares until such Stockholder's
receipt of (i) copies of the supplemented or amended Prospectus
contemplated by subsection 5.05(d) hereof, or until counsel for Parent
shall have determined that such disclosure is not required due to
subsequent events, (ii) notice in writing from Parent that the use of
the Prospectus may be resumed, (iii) copies of any additional or
supplemental filings with respect to the Prospectus, or (iv) the
expiration of the Suspension Period. In the event Parent shall give
49
<PAGE> 54
any such notice, the time period regarding the filing of the
Registration Statement set forth in subsection 5.04(a) hereof shall be
extended by the number of days during the period from and including
the date of the giving of such notice pursuant to subsection 5.05(e)
hereof to and including the date when each Stockholder covered by such
Registration Statement shall have received the copies of the
supplemented or amended Prospectus contemplated by this subsection
(g); and
(h) Parent agrees to use its best efforts to cause the Registered
Shares covered by the Registration Statement to be registered with or
approved by such other governmental agencies or authorities as may be
necessary to enable the Stockholders thereof to consummate the
disposition of such Registered Shares, subject to the proviso
contained in subsection (c) above, and cause all Registered Shares to
be listed on each securities exchange or national quotation system on
which Parent's Common Stock is then listed by no later than the date
on which the Registration Statement is declared effective.
Section 5.06. INDEMNIFICATION.
With respect to the Registration Statement, the Stockholders and Parent
shall be bound by the indemnification obligations set forth in the Investment
Letter.
Section 5.07. EXCULPATION FOR DIRECTOR LIABILITY.
Parent shall, and Parent shall cause the Company to, keep in effect
provisions of the Certificate of Incorporation and Bylaws of the Company
providing for exculpation of director liability and indemnification of
directors, officers and agents of the Company to the fullest extent permitted
under the Delaware Code, which provisions shall not be amended except as
required by applicable law. Parent shall, and Parent shall cause the Company to,
keep in effect and cause compliance with the terms and conditions of the
indemnification agreements, if any between the Company and each of its directors
and officers in effect as of the date of this Agreement.
Section 5.08. LEASE TERMINATION.
(a) The Company shall no later than May 31, 1999 have either (i)
terminated its leases of the buildings located at 4200 Research Forest
Drive, The Woodlands, Texas and 8701 New Trails, Suite A, The
Woodlands, Texas (collectively, the "Property Leases"), or (ii)
subleased each of the Property Leases for at least that rental rate
that will fully discharge the obligations and liabilities of the
Company under the Property Leases; provided, however, that such
sublease(s) shall terminate no later than November 19, 1999.
Notwithstanding the foregoing, the parties agree and acknowledge that
it is the intent of the Company to relocate the Company's operations
to Fort Collins, Colorado and in connection therewith, commencing on
the Closing Date, the Company intends to begin the process of moving
all or part of the laboratory equipment, furniture, office equipment,
supplies and other personal property from the Company's offices to the
Parent's offices in Fort Collins, Colorado.
50
<PAGE> 55
(b) The Principal Stockholders agree that the Principal
Stockholders shall be liable for all lease payments and obligations
arising out of the Property Leases for the period after May 31, 1999
and further agree that if the actions of the Company in the relocation
of all or part of the laboratory equipment, furniture, office
equipment, supplies and other personal property from the Company's
offices to the Parent's offices in Fort Collins, Colorado and the
winding down of the Company's operations in The Woodlands, Texas shall
cause or be deemed to cause a default or breach under the Property
Leases, then the liability (other than liability by reason of damage
caused to the facilities during the moving process) associated with
such default or breach shall be the liability of the Principal
Stockholders and be subject to the indemnification obligations of the
Principal Stockholders as set forth in the Indemnity and Escrow
Agreement. Any liability of the Principal Stockholders arising under
this Section 5.08(b) shall not be subject to the Floor (as defined in
the Indemnity and Escrow Agreement).
(c) Prior to or concurrent with the Closing, the Company shall
have obtained a waiver from the landlord under the Property Leases to
the effect that the landlord acknowledges that the Company is moving
its operations to the Parent's office in Fort Collins, Colorado and
waiving any default arising from the removal and relocation of any
personal property of the Company located at the Property Lease
locations.
Section 5.09. PRODUCTS LIABILITY INSURANCE.
Parent hereby covenants and agrees that it will use its best efforts to
maintain, or cause the Company to maintain, tail products liability insurance
coverage in amounts no less than currently maintained by Company (and with a
deductible no greater than the Company's deductible) to cover products liability
claims with respect to Company Products sold prior to the Closing until the
expiration of the representation and warranty in Section 3.09 of the Agreement.
If solely through the fault of Parent or Company, but not otherwise, such
product liability insurance is not maintained, then the representation and
warranty in Section 3.09 shall expire automatically as of the last day of such
insurance coverage.
ARTICLE VI
SURVIVAL, INDEMNIFICATION
The covenants, agreements, representations and warranties of the
parties hereto contained in this Agreement or in any certificate or other
writing delivered pursuant hereto or in connection herewith shall survive the
Closing and shall expire and be of no further force or effect at 12:00 a.m. on
November 24, 1999. Notwithstanding the previous sentence, (i) the covenants and
warranties contained in Section 3.25(c) shall survive for the period of time
specified therein; (ii) the covenant contained in Section 5.08 shall continue
until the termination of the leases referred to therein; and (iii) the
covenants, agreements, representations and warranties contained in Sections
3.09, 3.13, 3.23, 5.07 and 5.09 shall survive until expiration of the statute of
limitations applicable to the matters covered thereby (giving effect to any
waiver, mitigation or extension thereof). Notwithstanding the preceding
sentence, any covenant, agreement, representation or warranty in respect of
51
<PAGE> 56
which indemnity may be sought under this Agreement shall survive the time at
which it would otherwise terminate pursuant to the preceding sentence, if
written notice of the inaccuracy or breach thereof giving rise to such right of
indemnity shall have been given to the party against whom such indemnity may be
sought prior to such time.
ARTICLE VII
GENERAL PROVISIONS
Section 7.01. NOTICES.
All notices, requests and other communications to any party hereunder
shall be in writing (including facsimile transmissions) and shall be deemed to
have been given if delivered personally or by commercial messenger or courier
service, or mailed by registered or certified mail (return receipt requested) or
sent via facsimile (with acknowledgment of complete transmission) to the parties
at the following addresses (or at such other address for a party as shall be
specified by like notice):
(a) if to Parent, to:
Atrix Laboratories, Inc.
2975 Midpoint Drive
Fort Collins, Colorado 80252
Attention: Dr. Charles P. Cox
Vice President, New Business Development
Telephone: (970) 482-5868
Facsimile: (970) 482-9765
with a copy to:
Morrison & Foerster LLP
5200 Republic Plaza
370 17th Street
Denver, Colorado 80202
Attention: Warren L. Troupe
Telephone: (303) 592-1500
Facsimile: (303) 592-1510
(b) if to the Company or the Principal Stockholders, to:
ViroTex Corporation
4200 Research Forest Drive, Suite 350
The Woodlands, Texas 77381
Attention: Jeffrey M. Soinski
President and CEO
Telephone: (281) 292-7671
Facsimile: (281) 292-6697
52
<PAGE> 57
with a copy to:
Cooley Godward LLP
4365 Executive Drive
Suite 1100
San Diego, CA 92121
Attention: Frederick T. Muto
Barbara L. Borden
Telephone: (619) 550-6000
Facsimile: (619) 453-3555
(c) If to the Stockholders' Representatives, to:
Anthony A. Brown
114 Golden Shadow Circle
The Woodlands, Texas 77381
Telephone: (281) 367-9718
Facsimile: (281) 298-9798
William T. Mullaney
Chairman
Ventures Medical, L.P.
16945 Northchase Drive, Suite 2150
Houston, Texas 77060
Telephone: (281) 873-5748 x12
Facsimile: (281) 873-5950
Notice so given shall be deemed given and received (i) if by mail on
the fourth calendar day after posting; (ii) by facsimile or personal delivery on
the date of actual transmission or personal delivery, as the case may be; and
(iii) if by overnight courier, on the next business day following the day such
notice is delivered to the courier service.
Section 7.02. DISCLOSURE SCHEDULE.
The Disclosure Schedule shall be arranged in separate parts
corresponding to the numbered and lettered sections contained in Articles III
and IV, as the case may be. The information disclosed in any numbered or
lettered part shall be deemed to be disclosed and incorporated in any other
numbered or lettered part where the relevance of such disclosure to another
numbered or lettered part would be reasonably apparent from such disclosure.
Section 7.03. INTERPRETATION.
The words "include," "includes" and "including" when used herein shall
be deemed in each case to be followed by the words "without limitation." The
table of contents and headings contained in this Agreement are for reference
purposes only and shall not affect in any way the meaning or interpretation of
this Agreement.
53
<PAGE> 58
Section 7.04. COUNTERPARTS.
This Agreement may be executed in one or more counterparts, all of
which shall be considered one and the same agreement and shall become effective
when one or more counterparts have been signed by each of the parties and
delivered to the other party, it being understood that all parties need not sign
the same counterpart.
Section 7.05. ENTIRE AGREEMENT; ASSIGNMENT.
This Agreement, the Exhibits hereto, the Disclosure Schedule, and the
Related Agreements (including the Indemnity and Escrow Agreement, the
Transmittal Letter and the Investment Letter) (i) constitute the entire
agreement among the parties with respect to the subject matter hereof and
supersede all prior agreements and understandings both written and oral, among
the parties with respect to the subject matter hereof, (ii) except as set forth
in Section 8.05 below, are not intended to confer upon any other person any
rights or remedies hereunder; and (iii) shall not be assigned by operation of
law or otherwise.
Section 7.06. THIRD PARTY BENEFICIARIES.
It is the intention of the parties that the Stockholders be considered
third party beneficiaries of the terms and provisions contained in this
Agreement, including but not limited to the rights, obligations and agreements
contained in Article II herein. Further, such Stockholders shall have a vested
right to enforce the provisions of Article II hereof upon compliance with the
terms and provisions contained in this Agreement.
Section 7.07. SEVERABILITY.
In the event that any provision of this Agreement or the application
thereof becomes or is declared by a court of competent jurisdiction to be
illegal, void or unenforceable, the remainder of this Agreement will continue in
full force and effect and the application of such provision to other persons or
circumstances will be interpreted so as reasonably to effect the intent of the
parties hereto. The parties further agree to replace such void or unenforceable
provision of this Agreement with a valid and enforceable provision that will
achieve, to the extent possible, the economic, business and other purposes of
such void or unenforceable provision.
Section 7.08. OTHER REMEDIES.
Except as otherwise provided herein, any and all remedies herein
expressly conferred upon a party will be deemed cumulative with and not
exclusive of any other remedy conferred hereby, or by law or equity upon such
party, and the exercise by a party of any one remedy will not preclude the
exercise of any other remedy.
54
<PAGE> 59
Section 7.09. GOVERNING LAW.
This Agreement shall be governed by and construed in accordance with
the laws of the State of Colorado, regardless of the laws that might otherwise
govern under applicable principles of conflicts of laws thereof. Each of the
parties hereto irrevocably consents to the exclusive jurisdiction and venue of
any court within the City and County of Denver, State of Colorado, in connection
with any matter based upon or arising out of this Agreement or the matters
contemplated herein, which matters are not subject to arbitration under Section
9.04, and agrees that process may be served upon them in any manner authorized
by the laws of the State of Colorado for such persons and waives and covenants
not to assert or plead any objection which they might otherwise have to such
jurisdiction, venue and such process.
Section 7.10. ARBITRATION.
All disputes and all other controversies or claims arising out of or
relating to this Agreement or any Related Agreements, or the breach thereof,
other than a claim for equitable relief, shall be settled by arbitration in
accordance with the Commercial Arbitration Rules of the American Arbitration
Association in Denver, Colorado. One arbitrator shall be selected by the
indemnifying party or parties, one arbitrator shall be selected by the
indemnified party, and the third arbitrator shall be chosen by the first two
arbitrators chosen. The cost and expense of arbitration shall be shared equally
by the parties to the arbitration, regardless of which party or parties prevail.
The arbitration shall be conducted in accordance with the following time
schedule unless otherwise mutually agreed to in writing by the parties: (i)
parties to the arbitration proceeding shall each appoint their respective
arbitrator within fifteen (15) business days after the end of the Notice Period;
(ii) within five (5) business days thereafter, such arbitrators shall appoint
the third arbitrator; (iii) promptly after appointment of the third arbitrator,
the arbitrators shall authorize the parties to conduct reasonable discovery,
including document productions and depositions, as specified by the arbitrators,
which discovery shall end no later than thirty days after the appointment of the
third arbitrator unless the arbitrators, with the consent of all parties, agree
to extend such period; (iv) the arbitrators shall schedule a hearing on the
dispute within 30 days after the date on which the discovery is scheduled to
end; and (v) within fifteen (15) business days after the date of the hearing
referenced in clause (iv) the arbitrators shall render their decision. The
decision or award of the arbitrators shall be final and binding upon the parties
hereto to the same extent and to the same degree as if the matter had been
adjudicated by a court of competent jurisdiction and shall be enforceable under
the Federal Arbitration Act.
Section 7.11. AMENDMENT.
This Agreement may be amended by the parties hereto at any time by
execution of an instrument in writing signed on behalf of each of the parties
hereto and the Stockholders' Representatives.
55
<PAGE> 60
Section 7.12. EXTENSION: WAIVER.
Parent, on the one hand, and the Company, on the other hand, may, to
the extent legally allowed, (i) extend the time for the performance of any of
the obligations of the other party hereto, (ii) waive any inaccuracies in the
representations and warranties made to such party contained herein or in any
document delivered pursuant hereto, and (iii) waive compliance with any of the
agreements or conditions for the benefit of such party contained herein,
provided such waiver or extension shall not adversely effect the Stockholders.
Any agreement on the part of a party hereto to any such extension or waiver
shall be valid only if set forth in an instrument in writing signed on behalf of
such party.
Section 7.13. RULES OF CONSTRUCTION.
The parties hereto agree that they have been represented by counsel
during the negotiation and execution of this Agreement and, therefor, waive the
application of any law, regulation, holding or rule of construction providing
that ambiguities in an agreement or other document will be construed against the
party drafting such agreement or document.
Section 7.14. KNOWLEDGE.
Whenever the term to the "knowledge of the Company," or similar phrase,
is used in this Agreement, such phrase shall mean the actual knowledge of the
Company's directors and executive officers and knowledge that could have been
obtained by the Company's executive officers with respect to those matters that
would cause a reasonable person, in a similar position, to investigate the
matter further and that could have been obtained from such investigation without
undue effort.
56
<PAGE> 61
IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be
duly executed by their respective authorized officer or person as of the day and
year first above written.
ATRIX LABORATORIES, INC.
By: /s/ JOHN E. URHEIM
------------------------------------------
John E. Urheim, Vice Chairman and Chief
Executive Officer
ATRIX ACQUISITION CORPORATION
By: /s/ JOHN E. URHEIM
------------------------------------------
John E. Urheim, President
VIROTEX CORPORATION
By: /s/ JEFFREY M. SOINSKI
------------------------------------------
Jeffrey M. Soinski, President and
Chief Executive Officer
57
<PAGE> 1
EXHIBIT 10.2
CERTIFICATE OF MERGER
OF
ATRIX ACQUISITION CORPORATION
INTO
VIROTEX CORPORATION
The undersigned corporation organized and existing under and by virtue of
the General Corporation Law of the State of Delaware (the "DGCL"),
DOES HEREBY CERTIFY:
FIRST: That the name and state of incorporation of each of the constituent
corporations of the merger are as follows:
Name State of Incorporation
---- ----------------------
Atrix Acquisition Corporation Delaware
ViroTex Corporation Delaware
SECOND: That an Agreement and Plan of Reorganization between Atrix
Laboratories, Inc., a Delaware corporation, Atrix Acquisition Corporation,
ViroTex Corporation and certain shareholders of ViroTex Corporation as named
therein (collectively, the "Parties") has been approved, adopted, certified,
executed and acknowledged by Atrix Acquisition Corporation and ViroTex
Corporation in accordance with the requirements of Section 251 of the DGCL.
THIRD: That the name of the surviving corporation of the merger is ViroTex
Corporation.
FOURTH: That the Certificate of Incorporation of ViroTex Corporation shall
be amended and restated in the form attached hereto as Exhibit A.
FIFTH: That the executed Agreement and Plan of Reorganization is on file at
the principal place of business of the surviving corporation, a copy of which
will be furnished, on request and without charge, to any Stockholder of any
constituent corporation. The address of the principal place of business of the
surviving corporation is 2579 Midpoint Drive, Fort Collins, Colorado 80525.
<PAGE> 2
IN WITNESS WHEREOF, the undersigned has caused this agreement to be duly
executed by its authorized officer as of this 24th day of November, 1998.
VIROTEX CORPORATION
By /s/ JEFFREY M. SOINSKI
---------------------------------------------
Jeffrey M. Soinski, President and Chief
Executive Officer
2
<PAGE> 3
EXHIBIT A
AMENDED AND RESTATED
CERTIFICATE OF INCORPORATION
OF
VIROTEX CORPORATION
IT IS HEREBY CERTIFIED THAT,
A. The present name of the corporation (hereinafter called the
"Corporation") is ViroTex Corporation. The name under which the Corporation was
originally incorporated is Viro-Tex Corporation, and the date of filing the
original certificate of incorporation of the Corporation with the Delaware
Secretary of State is May 4, 1988.
B. The certificate of incorporation of the Corporation, as amended, is
hereby amended in its entirety by deleting all of the original Articles and
substituting in lieu thereof the new Articles set forth in the Amended and
Restated Certificate of Incorporation hereinafter provided for.
C. The provisions of the certificate of incorporation of the Corporation as
heretofore amended, and as herein amended, are hereby restated and integrated
into the single instrument which is hereinafter set forth, and which is entitled
Amended and Restated Certificate of Incorporation of ViroTex Corporation,
without any further amendments other than the amendments herein certified.
D. The amendments and the restatement of the certificate of incorporation
herein certified have been duly adopted by the stockholders in accordance with
the provisions of Sections 228, 242 and 245 of the General Corporation Law of
the State of Delaware.
E. The certificate of incorporation of the Corporation, as amended and
restated herein, shall at the effective time of this amended and restated
certificate of incorporation, read as follows:
3
<PAGE> 4
AMENDED AND RESTATED
CERTIFICATE OF INCORPORATION
OF
VIROTEX CORPORATION
1. The name of the Corporation is ViroTex Corporation.
2. The address of its registered office in the State of Delaware is 1013
Centre Road, Wilmington, 19805, County of New Castle. The name of its registered
agent at such address is Corporation Service Company.
3. The nature of the business of the Corporation and the objects or
purposes to be transacted, promoted or carried on by it are as follows: To
engage in any lawful act or activity for which corporations may be organized
under the General Corporation Law of the State of Delaware.
4. The total number of shares of all classes of stock that the Corporation
is authorized to issue is One Thousand (1,000) shares of Common Stock with a par
value of $.001 per share.
5. The board of directors is expressly authorized to make, alter, or repeal
the bylaws of the Corporation.
6. Elections of directors need not be by written ballot unless the bylaws
of the Corporation shall so provide.
7. Whenever a compromise or arrangement is proposed between this
Corporation and its creditors or any class of them and/or between this
Corporation and its stockholders or any class of them, any court of equitable
jurisdiction within the State of Delaware may, on the application in a summary
way of this Corporation or of any creditor or stockholder thereof, or on the
application of any receiver or receivers appointed for this Corporation under
the provisions of Section 291 of Title 8 of the Delaware Code or on the
application of trustees in dissolution or of any receiver or receivers appointed
for this Corporation under the provisions of Section 279 of Title 8 of the
Delaware Code order a meeting of the creditors or class of creditors, and/or of
the stockholders or class of stockholders of this Corporation, as the case may
be, to be summoned in such manner as the said court directs. If a majority in
number representing three-fourths in value of the creditors or class of
creditors, and/or of the stockholders or class of stockholders of this
Corporation, as the case may be, agree to any compromise or arrangement and to
any reorganization of this Corporation as a consequence of such compromise or
arrangement, the said compromise or arrangement and the said reorganization
shall, if sanctioned by the court to which the said application has been made,
be binding on all the creditors or class of creditors, and/or on all the
stockholders or class of stockholders, of this Corporation, as the case may be,
and also on this Corporation.
4
<PAGE> 5
8. The Corporation reserves the right to amend, alter, change or repeal any
provision contained in this Certificate of Incorporation, in the manner now or
hereafter prescribed by statute, and all rights conferred upon stockholders
herein are granted subject to this reservation.
9. To the fullest extent permitted by Delaware statutory or decisional law,
as amended or interpreted, no director of this Corporation shall be personally
liable to the Corporation or its stockholders for monetary damages for breach of
fiduciary duty as a director. This Article 9 does not affect the availability of
equitable remedies for breach of fiduciary duties.
IN WITNESS WHEREOF, the undersigned has caused this document to be duly
executed by its authorized officer as of this 24th day of November, 1998.
VIROTEX CORPORATION
By /s/ JEFFREY M. SOINSKI
---------------------------------------------
Jeffrey M. Soinski, President and Chief
Executive Officer
5
<PAGE> 1
EXHIBIT 99.1
ATRIX LABORATORIES ACQUIRES VIROTEX; GAINS FOUR SHORT-ACTING
DRUG DELIVERY TECHNOLOGIES
FORT COLLINS, Colo. (November 30, 1998) * Atrix Laboratories, Inc.
(NASDAQ NM: ATRX) today announced that it has acquired ViroTex Corporation, a
privately owned drug delivery company. The acquisition expands the company's
drug delivery technology base and is expected to accelerate and diversify future
revenue growth.
"The addition of ViroTex will allow us to build on the success of our
core ATRIGEL(R) drug delivery platform with important complementary technologies
that we expect will significantly enhance shareholder value," said John Urheim,
vice chairman and chief executive officer of Atrix. "The acquisition includes a
current revenue stream of royalties from Viractin(R) (tetracaine 2%), an
over-the-counter (OTC) product for cold sores and fever blisters marketed by
J.B. Williams Company, and a product pipeline of four near-term OTC products for
oral care and skin care, as well as two prescription products ready to enter
Phase I clinical trials for oral care and severe acne."
Under the terms of the acquisition agreement, which has been approved
by each company's board of directors, Atrix has acquired ViroTex for $7.5
million in cash and $500,000 in Atrix common stock. Also, ViroTex shareholders
may earn up to an additional $3 million in Atrix common stock based on the
success of ViroTex's products and technologies in the marketplace.
Atrix expects this acquisition to contribute approximately $2 to $3
million to the company's 1999 revenues and to favorably impact 1999 earnings.
The transaction will be accounted for as a purchase, and approximately $3.5
million of the purchase price is expected to be charged to in-process research
and development and will be reflected in Atrix Laboratories' financial results
for the fourth quarter ended December 31, 1998.
Founded in 1988 and headquartered in The Woodlands, Texas, ViroTex
develops OTC and prescription products based on proprietary drug delivery
systems that provide topical and transmucosal delivery of medications requiring
fast onset of action. The ViroTex immediate-release systems complement Atrix's
ATRIGEL(R) drug delivery technology, which releases drugs for extended periods
of time ranging from days to months. Both ATRIGEL and the ViroTex systems can be
engineered for either local or systemic delivery of a variety of small
molecules, peptides, proteins and vaccines.
"Adding the ViroTex technologies significantly strengthens our research
and development base, and creates both immediate and longer-term opportunities
to provide enabling biodegradable drug delivery systems for a variety of
medical, dental and veterinary applications," said Dr. Richard L. Jackson,
Atrix's senior vice president of research and development. "In addition to
existing ViroTex products, we are acquiring four polymer- and solvent-based drug
delivery technologies that will allow Atrix to offer pharmaceutical and
biotechnology companies an array of immediate and sustained-release
biodegradable drug delivery systems to meet their product development needs."
<PAGE> 2
Jeffrey Soinski, president and chief executive officer of ViroTex,
commented: "Although ViroTex has been successful in developing OTC products such
as Viractin on our own, we realize that the great potential represented by our
technologies can best be achieved by combining with another drug delivery
company. We are very excited about joining forces with Atrix and working
together to get our products into the marketplace."
"The acquisition of ViroTex is an excellent first step in expanding our
drug delivery business beyond the ATRIGEL technology," Urheim said. "Because
development times for OTC products oftentimes are far shorter than for
prescription products, we believe that the ViroTex acquisition can contribute to
the company's near-term growth. When combined with sales of our ATRIDOX product,
this will help us expand revenues more quickly as we complete, and in some cases
accelerate, the development of long-term prescription drug projects. In
addition, several of these products can be manufactured in our state-of-the-art
facility for company-wide operating efficiencies."
In September 1998 Atrix received U.S. Food and Drug Administration
approval for ATRIDOX(R) (doxycycline hyclate 10.0% in the ATRIGEL delivery
system), a new prescription antibiotic therapy that kills the bacteria
associated with periodontal disease. The ATRIGEL technology is now being used to
develop additional products for dentistry, oncology and orthopedics.
The ViroTex drug delivery technologies include Bioerodible Mucoadhesive
(BEMA*) film, which adheres to the mucosal tissue of the mouth or vagina and
allows the rapid or controlled delivery of medication through the tissue as the
film dissolves away; the Mucocutaneous Adsorption (MCA) system, a moisture
resistant, film-forming gel or aerosol that binds drugs to skin or mucosal
tissue for more efficient drug delivery; the Biocompatible Polymer (BCP) system,
which delivers drug to a wound and dries to a protective film to create a moist
environment for healing; and the Solvent/Microparticulate (SMP) system, which
combines dissolved drug compounds with a microparticulate suspension of the drug
in a single formulation, allowing the medication to be delivered in two stages
to improve the absorption of relatively insoluble active compounds.
Atrix Laboratories, Inc. develops, manufactures and markets dental,
medical and veterinary products based on its proprietary ATRIGEL(R)
biodegradable polymeric technology, which can be used for a broad range of drug
delivery and biomaterial applications. Additional information is available on
the Atrix Laboratories, Inc. Web site at http://www.atrixlabs.com.
Forward-looking statements in this release involve a number of risks
and uncertainties including, but not limited to regulatory reviews, product
demand, pricing, market acceptance, changing economic conditions, risks in
product and technology development, the effect of the company's accounting
policies and other risk factors detailed in the company's SEC filings.
# # #
2
